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COMPETITION BETWEEN GRB2 AND PLCγ1 FOR BINDING TO
FGFR2 REGULATES PHOSPHOLIPASE AND PTEN ACTIVITY,
LEADING TO CELL INVASION AND PROLIFERATION

By Zahra Timsah, Ph.D.
Supervisory Professor: John E. Ladbury, Ph.D.

Fluctuations in the relative concentrations of proteins in non-stimulated cells
can lead to aberrant signaling. In a novel interaction, the SH3 domain of Plcγ1
competes with the SH3 domain of Grb2 for binding to FGFR2 in a
concentration-dependent
concentrations

of

Grb2

manner.
lead

Consequently,
to

reduction

receptor-dependent

of

cellular

recruitment

of

unphosphorylated Plcγ1. Bringing of the phospholipase to the membrane in this
way upregulates its activity, resulting in increased PIP2 turnover to IP3 and DAG
resulting in elevated cellular calcium levels. These signaling events increase
cell migration and invasion. A further consequence of the depletion of PIP2 is
the inhibition of PTEN phosphatase activity. Inhibition of PTEN activity leads to
the accumulation of PIP3, which recruits Akt leading to its phosphorylation and
activation. Therefore, depletion of Grb2 indirectly leads to activation of the
proto-oncogene

Akt

inducing

phenotypic

alterations

characteristic

of

tumorigenesis including anchorage-independent cell growth and tumor
formation in mice models.
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Chapter One: Introduction
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FGFR signaling and its role in cancer
Fibroblast growth factor (FGF) signaling mediates and controls many
physiological functions. The FGF family is composed of 18 different ligands that
act through 4 conserved receptor tyrosine kinases (RTKs): fibroblast growth
factor receptor (FGFR) 1, FGFR2, FGFR3, and FGFR4 (Fig 1.1). A fifth
receptor, FGFR5, is known to negatively regulate signaling even though it lacks
a tyrosine kinase (TK) domain. FGFs are secreted glycoproteins that are
sequestered via heparan-sulfate proteoglycans (HPSGs) to the extracellular
matrix or cell surface. Heparinases, FGF binding proteins, and proteases
release FGFs allowing them to bind to HPSGs (Fig 1.1). The specificity of the
ligand-receptor interaction is mediated by FGFR alternative splicing and tissue
specific expression of both FGFs and FGFRs (1).
FGFRs rely on ligand-dependent dimerization (1) or protein-dependent
dimerization, as is the case for FGFR2 (2). Dimerization causes a
conformational change that activates the intracellular kinase domain, resulting
in the trans-phosphorylation of the intracellular tail and TK domains.
Phosphorylated tyrosine residues on the receptor provide binding sites for
downstream effectors allowing for a cascade of downstream signals to occur,
ultimately influencing mitogenesis and differentiation (1).	
  
In the absence of extracellular stimulation, FGFR2 binds to the C-terminal Src
Homology 3 (SH3) domain of growth factor receptor-bound protein 2 (Grb2)
(2,3). The Grb2 dimer recruits two molecules of FGFR2 to form a
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heterotetramer. In this state ‘background' receptor kinase activity is limited to
the phosphorylation of tyrosine residues (Y) 653 and 654 in the activation loop
of FGFR2. Furthermore, the receptor is unable to recruit downstream effector
proteins or initiate signal transduction. Upon extracellular growth factor
stimulation, FGFR2 dimerization is stabilized, leading to the upregulation of
autophosphorylation. Full activation of the receptor induces phosphorylation of
Grb2 on Y209. This results in the release of Grb2, thus allowing other
downstream proteins to be recruited to FGFR2 (Fig 1.2).

Fig 1.1 FGFR structure and control of ligand specificity. a) The structure of
the FGFR complex comprises two receptor molecules, two FGFs, and one
HSPG chain. FGFs bind to cell surface HSPGs with low affinity and to FGFRs
with high affinity. FGFRs are composed of three extracellular immunoglobulin
(Ig) domains, a single transmembrane helix, and an intracellular split tyrosine
kinase (TK) domain. The second and third Ig domains form the ligand-binding
pocket and have distinct domains that bind both FGFs and HSPGs. Ligandbinding specificity is generated by alternative splicing of the Ig III domain. The
first half of Ig III is encoded by an invariant exon (IIIa), which is spliced to either
exon IIIb or IIIc.b) FGFR2-IIIb and FGFR2-IIIc ligands are shown in orange and
green, respectively.

	
  

3	
  

Fig 1.2 Model of the molecular mechanism of Grb2-mediated activation of
FGFR2. Dimeric Grb2 (SH3 domains—red; SH2 domain—yellow) is bound via
its C-SH3 domain to the C-terminal region of FGFR2 (blue), resulting in the
formation of a 2:2 heterotetramer and receptor predimerization. The kinase
domains of FGFR2 (blue ovals) permit the phosphorylation of Y653 and Y654.
The binding of FGF (orange) and HSPG (red line) to FGFR2 induces a
conformational change that results in Grb2 phosphorylation by the FGFR2
kinase domain. Phosphorylated Grb2 is released from the receptor. FGFR2
kinase domains become fully activated and transphosphorylate tyrosine
residues formerly buried in the Grb2-receptor interface (adapted from Lin et al.,
2012 with permission from Cell).
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In addition to Grb2, many other adaptor proteins bind to FGFRs. For example,
fibroblast

growth

factor

receptor

substrate

2

(FRS2)

binds

to

the

juxtamembrane region of FGFRs through its phosphotyrosine binding (PTB)
domains. Phosphorylated FRS2 can recruit son of sevenless (SOS) and in turn
activate the mitogen activated protein kinase (MAPK) pathway. FGFRs can
directly or indirectly (via adaptor proteins) activate four pathways: rat sarcoma
(RAS)/ rapidly accelerated fibrosarcoma (RAF)/MAPK, phosphatidylinositide 3kinase (PI3K)/-AKR mouse T-cell lymphoma protein (Akt; protein kinase B),
signal transducer and activator of transcription (STAT), and phospholipase Cγ1
(Plcγ1) (1).
The significance of FGFR signaling in tumorigenesis was shown by a screen of
1000 somatic mutations in the coding exons of 518 protein kinase genes in 210
cancers (4). For example, bladder cancer has a well-established link to FGFR
mutations. FGFR2 mutations, which are usually extracellular and equal to the
activating germline mutations found in craniosynostosis syndromes, have been
found in 12% of endometrial carcinomas (5). Endometrial cancer-derived cell
lines are sensitive to FGFR tyrosine inhibitors,which reflects oncogenic
addiction to mutant-activated FGFR.
Protein recruitment to activated FGFR2 usually occurs via the C-terminal region
of the receptor. C-terminal sequence splicing leads to the derivation of a major
group of isoforms. One should note that perturbation of the amino acid
sequence in this region might have pathogenic and tumorigenic outcomes. For
example, point mutations in the C-terminal region of FGFR2 have been linked
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to melanoma (6), and deletions of the C-terminal sequence, which are found in
a majority of human breast carcinoma cells, have enhanced transforming
activity (7,8). Deletions in the FGFR2 C-terminal sequence are also found in
bladder, stomach, and gastric cancers (9-12).
Grb2: Function and importance
Grb2 is a ubiquitously expressed adaptor protein that is generally considered to
play a passive role in RTK signaling because it does not possess intrinsic
enzymatic activity. Grb2 consists of a Src Homology 2 (SH2) domain
sandwiched between N and C-terminal SH3 domains (Fig 1.3). The SH2
domain binds phosphorylated tyrosine residues on docking proteins or
receptors. The N and C-terminal SH3 domains recognize proline-rich sites on
proteins, such as SOS (13), or receptors, such as FGFR2 (2).
Grb2 is critical for the regulation of mitogen-independent FGFR2 heterotetramer
formation (2) and inhibits tyrosine-protein phosphatase non-receptor type 11
(PTPN11 or Shp2)-mediated FGFR2 activation loop tyrosine dephosphorylation
(3). Thus, evidence indicates that Grb2 is not a passive adaptor protein but
rather a fundamental positive and negative regulator of FGFR2 phosphorylation
and downstream signal transduction (3).
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Y209	
  

Fig 1.3 Grb2 domains. Grb2 consists of one phosphotyrosine (pY)-binding
SH2 domain sandwiched between two proline rich motif-binding SH3 domains.

Plcγ1: Function and importance
Mitogen-induced stimulation of various cell surface receptors activates the
cytoplasmic lipase phospholipase C gamma (Plcγ). The two Plcγ isoforms 1
and 2 act downstream of receptors with and without intrinsic TK activity. The
Plcγs are unique amongst the phospholipases in having the split phospholipase
domain

separated

by

functional

domains.

The

catalytic

domain

of

phospholipases is composed of X and Y boxes, which are two sequentially
discrete regions separated by an extended linker region (X/Y linker).The X/Y
linker includes sequentially a split PH domain, two SH2 domains (NSH2 and
CSH2, respectively) and an SH3 domain (Fig 1.4). Activated Plcγ1 hydrolyzes
the membrane lipid phosphatidylinositol 4,5-bisphosphate (PI[4,5]P2 or PIP2) to
form inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 mediates
Ca2+ mobilization, whereas DAG activates protein kinase C (PKC) signaling.
Plcγ1 activation requires membrane translocation. Plcγ1 is phosphorylated on
four main tyrosines: 472, 771, 783, and 1254. Phosphorylation on Y783 has
been reported to be required for Plcγ1activation.
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Fig 1.4 Plcγ1 domains. Schematic illustration of the sequence of Plcγ1
domains. PH: pleckstrin homology domain. EF: EF-hand calcium-binding
domain. X and Y: catalytic domains. P and H: split PH domain. NSH2 and
CSH2: N-terminal and C-terminal Src homology 2 domains. SH3: Src
homology-3 domain. C2: protein kinase C conserved region 2 domain.SH2
(yellow) and SH3 (red) domains shown as circles.
Plcγ1 phosphorylation on Y1254 was shown to be required for maximal growth
factor-induced stimulation, whereas phosphorylation on Y771 was proposed to
act

as

a

negative

regulator.

Some

studies

have

also

shown

that

phosphorylation of both Y775 and Y783 play equally important roles in
Plcγ1activation (14).
Other studies and as shown in Fig 1.5 reported that the catalytic domain of this
lipase is inhibited by its CSH2 domain. Upon stimulation, NSH2 domain binds to
the receptor leading to receptor-mediated Plcγ1 phosphorylation on Y783. This
consequently induces a conformational rearrangement that releases the
autoinhibition of the enzymatic activity(15).
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Fig 1.5 Mechanism for phosphorylation-dependent Plcγ1 activation. In the
non-stimulated state, the catalytic domain (red cylinder) of Plcγ1 is autoinhibited by the CSH2 domain (yellow cylinder). Receptor activation provides a
pY (green dot) docking site for the NSH2 domain (yellow cylinder) of the lipase,
resulting in its translocation to the plasma membrane for site-specific tyrosine
phosphorylation by RTKs. Tyrosine phosphorylation of Plcγ1 induces direct
interactions with the CSH2 domain. Engagement of the CSH2 domain by
phosphorylated tyrosine induces structural rearrangements of the CSH2 domain
with respect to the catalytic domain, leading to the release of auto-inhibition.
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Plcγ1 has many important functions in the intracellular transduction of receptormediated tyrosine kinase activators. It is also considered to be critical in
mediating metastasis. Tumor metastasis is the ability of cancer cells to spread
from a primary site and form tumors at distant sites. It is a multistep process
that

involves

local

invasion,

followed

by

intravasation

and

survival,

extravasation, initiation, and maintenance of micrometastases at distant sites,
and vascularization of resultant tumors (16) (Fig 1.6). Cell motility and invasion
play an indispensable role in metastasis; therefore, identification of involved
proteins and characterization of the underlying mechanisms regulating cell
motility are essential to understanding metastasis development.
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Fig 1.6 A schematic of the metastatic process a) An in situ cancer
surrounded by an intact basement membrane. b) Invasion requires changes in
cell–cell and cell–extracellular matrix adherence, destruction of proteins in the
matrix and stroma, and motility. Metastasizing cells enter distant tissues by
means of c) the lymphatics (pink oval) d) the circulation (red ovals represent
endothelial cells). e) This is followed by survival and arrest of tumor cells and
extravasation from the circulatory system. Metastatic colonization (here in the
lungs) occurs through single cells, which can develop into angiogenic
metastases.
Directed cell migration is regulated by growth factors and chemokines that bind
and activate specific receptors, such as RTKs, which activate cytoskeleton
rearrangement and cellular motility via a network of signaling pathways.
Activated Plcγ1 plays a decisive role in both cytoskeletal changes and migratory
ability associated with the metastatic process. Plcγ1 is highly expressed in
metastatic colorectal cancer and breast carcinomas. Plcγ1 is critical for breast
cancer cell migration and invasion, and down-regulation of its lipase activity has
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been shown to inhibit the metastasis of human MDA-MB-231 breast cancer
cells to lung in an in vivo mouse model (17). However, the mechanism by which
this lipase induces metastasis or the domains involved require further
investigation.

PTEN: Function and importance
Phosphatase and tensin homolog (PTEN) is a phosphatidylinositol phosphate
(PIP) phosphatase specific for the 3-position of the inositol ring. PTEN has been
shown to have activity towards PIP, PI(3,4)P2, and phosphatidylinositol (3,4,5)triphosphate (PI(3,4,5)P3 or PIP3) in vitro. However, PIP3 is the most important
substrate in vivo (Fig 1.7). PIP3 (generated by PI3K via the phosphorylation of
PIP2) provides a binding site for many PH domain-containing signaling proteins
such as Akt and 3-phosphoinositide dependent protein kinase-1 (PDK1). Thus,
PTEN via PIP3 can affect a large variety of physiological processes in both
developing and adult organisms. PIP3 is best known for its promotion of cell
proliferation and survival by inducing phosphorylation and activation of Akt
kinase.
PTEN is involved in several pathological processes and is inactivated or deleted
in many tumor types where the frequency of tumor-associated mutations rivals
that of the p53 tumor suppressor (18). Indeed it is considered to be the second
most highly mutated oncogene.
The substrate of PTEN, PIP3, is important in chemotaxis. During chemotaxis,
PIP3 localizes sharply to the leading edge of the cell to regulate the direction
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and formation of pseudopods at the cell anterior. Such an effect, however, also
requires PIP2-regulated localization of PTEN to the cell posterior (19).
PTEN is regulated by numerous molecular mechanisms generating a
continuum of functional PTEN levels in sporadic cancers and inherited
syndromes. PTEN function can be compromised by genetic mutations, which
result in a heterozygous loss (50%) or a homozygous loss (100%) of function.
In addition, several PTEN-interacting proteins can either positively or negatively
regulate PTEN function. Furthermore, disruption of competing endogenous
RNA (ceRNA) networks, epigenetic silencing, transcriptional repression,
microRNA (miRNA) regulation, post-translational modifications, and aberrant
localization can lead to subtle or significant changes in PTEN function (20).
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Fig 1.7: PTEN/PI3K/Akt pathway. PTEN opposes PI3K function to inactivate
Akt signaling. Following PTEN loss or down-regulation the resulting
accumulation of PIP3recruits the pleckstrin homology (PH) domain-containing
proteins Akt and PDK1 to the membrane. Akt is then activated by
phosphorylation at threonine 308 (T308) by PDK1 and phosphorylation at
serine 473 (S473) by PDK2 (mTORC2; composed of mammalian target of
rapamycin [mTOR], DEP domain-containing mTOR-interacting protein
[DEPTOR], target of rapamycin complex subunit LST8 [mLST8], mammalian
stress-activated protein kinase interacting protein 1 [mSIN1], proline-rich protein
5 [PROTOR], and rapamycin-insensitive companion of mTOR [RICTOR]). At
the membrane, association with carboxyl-terminal modulator protein (CTMP)
prevents Akt phosphorylation and hence, its full activation. Phosphorylation of
CTMP results in the release of Akt and its subsequent phosphorylation.
Activated Akt drives cell survival, proliferation, and cellular metabolism through
inhibitory/activatory phosphorylation of downstream proteins.
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Akt: Function and importance
Akt is a serine/threonine kinase that was originally identified as a homologue of
the v-Akt oncogene from a transforming retrovirus in a spontaneous thymoma
of a mouse. There are three members of the Akt family (Akt 1, Akt 2, and Akt 3)
with certain isoform-specific features. On PI3K activation, the PH domain of Akt
binds to PIP3. This leads to the phosphorylation of Akt at threonine 308 and
serine 473 and its full activation(Fig 1.7).
Activated Akt regulates multiple processes, such as cellular proliferation,
apoptosis, and glucose metabolism, through its well-characterized downstream
effectors. Akt can be inactivated by CTMP which binds to Akt preventing its
phosphorylation and downstream signaling. Moreover, overexpression of CTMP
can reverse the phenotype of v-Akt-transformed cells (Fig 1.7). Akt is also
regulated by its association with heat shock protein 90 (HSP90), which protects
it from protein phosphatase 2A (PP2A)-mediated dephosphorylation (21,22).
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Chapter Two: SH3 domains of Grb2 and Plcγ1
compete for the same binding site on FGFR2
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Background
Recently, Grb2 has been shown to form a kinase-active heterotetramer with two
molecules of FGFR2 in non-stimulated cells (2, 3, 23). This causes the
phosphorylation of activation loop tyrosine residues, which is inadequate to
cause downstream activation of signaling pathways. Grb2 binds FGFR2
through its C-terminal SH3 domain; therefore, this protein complex formation
occurs independently of growth factor stimulation and tyrosine phosphorylation.
Thus, Grb2 can prevent aberrant downstream signaling by acting as a
concentration-dependent control protein.
The physiological importance of maintaining an elevated Grb2 concentration is
highlighted through database analysis (Fig 2.1). Database analysis showed that
FGFR2-expressing tumor tissue samples with low concentrations of Grb2
display concomitant high expression levels of another FGFR2 ligand, Plcγ1.
Low Grb2 expression and increased expression of Plcγ1 have been linked with
the metastatic potential of many types of cancers. Therefore, investigation of
the molecular basis of this inverse relationship between Grb2 and Plcγ1 protein
concentrations and its effect on metastatic outcome is likely to be highly
important.
To investigate this relationship one should understand the function and
molecular basis of activation of both proteins. Upregulation of Plcγ1 activity
usually occurs when the NSH2 domain of Plcγ1 binds to a cognate site on
FGFR2 (pY769; 24-26). Once bound to the receptor, Plcγ1 becomes
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phosphorylated on several tyrosine residues, including Y775 and Y783, within
the X/Y linker region (27,28). This is followed by the intramolecular binding of
CSH2 to pY783 which activates the Plcγ1 by inducing a gross conformational
change that releases the auto-inhibition (15,29-31). Access to plasma
membrane-embedded phospholipids is facilitated by the binding of the Nterminal PH domain to PIP3 (32).
On the other hand, the ubiquitously expressed adaptor protein,Grb2, which
does not possess enzymatic activity, is involved in numerous RTK signaling
events. This protein is best known for its role in linking activated RTKs to the
guanine nucleotide exchange factor SOS to upregulate the downstream MAPK
pathway in growth factor-stimulated cells. Also, Grb2 is critical in forming a
stable heterotetramer with FGFR2, thus maintaining homeostasis in nonstimulated cells (2,23). Upon FGFR2 stimulation, Grb2 is phosphorylated and is
released from the receptor. Thus, it plays a dual regulatory role in FGFR2mediated signaling in stimulated and non-stimulated cells.
RTK-mediated signal transduction is initiated through provision of cognate,
phosphorylated binding sites to downstream signaling targets by the action of
growth factor-dependent up-regulation of the receptor kinase. This mechanism
represents a level of control that is imposed by the requirement of specific
kinase phosphorylation precluding the effects of random binding events and
fluctuation of local protein concentrations. Here, we demonstrate that Grb2
constitutively controls the stimulation-independent recruitment of Plcγ1 to
FGFR2 and its subsequent membrane localization and activation through direct
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inhibition of a mutual binding site on the receptor. Therefore, this interaction is
dependent on protein concentration and relative equilibrium binding constants
and not phosphorylation status of the proteins of interest.

Figure 2.1 Metastatic potential is dependent on expression levels of Plcγ1
and Grb2.The Grb2 expression level in cancer cell lines was based on data
extracted from Gene Expression Omnibus (GEO) website (accession number:
GSM127198). The heat map was generated using the R Console Statistical
Program. The data shown only includes 20 cell lines out of 60 cells lines used in
the original proteomic-based profiling. Cancer types were chosen based on the
expression of FGFR2 and ability to form macrometastasis. Adherent cell lines
were selected for compatibility and comparability with the focus of this work;
therefore, central nervous system cancer cell lines, leukemic cell lines, and
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melanoma cell lines were not included. Cell lines were classified as having high
relative metastatic potential (H) or low relative metastatic potential (L) based on
extensive literature search. Plcγ1 and FGFR2 expression levels in tissues were
extracted from thehttp://www.proteinatlas.org/website and verified by literature
search. The percentage of protein expression in the tissues was based on the
level of antibody staining, which can be found in the “Cancer Tissue Summary”
provided by the website.
Methods
Cells
Human embryonic kidney 293T (HEK293T), and human squamous carcinoma,
A431 epidermoid carcinoma were maintained in Dulbecco’s modified Eagle’s
high glucose medium (DMEM). DMEM was supplemented with 10% (vol/vol)
fetal bovine serum (FBS) and 1% antibiotic/antimycotic (Lonza) in a humidified
incubator at 37°C with 10% CO2. HEK293T cells stably expressing FGFR2 with
a C-terminal GFP fusion (FGFR2-GFP) were produced as previously described
and used throughout except in stated experiments in which parental cell lines
were adopted (45). Grb2 (G2i), and Plcγ1 (Pγi) knockdown cells were
generated by infecting cells Grb2 shRNA and Plcγ1 shRNA lentiviral particles,
respectively, followed by selection with 7 µg/ml puromycin. Controls cells (Ci)
were infected with scrambled shRNA lentiviral particles. Knockdown of Grb2
and Plcγ1 in surviving cells was confirmed by western blot. Cells were serum
starved overnight prior to stimulation with FGF9 for 30 min.
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Molecular Cloning
Truncated Plcγ1 polypeptides SH223 (residues 550-848) and SH3 (residues
795-848) were made. For SH223, individual point mutations (R586A and
R694A) were generated in NSH2 and CSH2. Tyrosine mutants and double
mutants (DM) were generated from full-length human influenza hemagglutin
(HA)-tagged Plcγ1. Three individual point mutations were generated in a GSTtagged polypeptide corresponding to the very C-terminal 58 amino acids
(P804A, P810A, and P813A). The kinase dead cytoplasmic portion of FGFR2
(residues 413-821) was generated through a point mutation (K517I).

Protein Expression and Purification
6Xhistidine, glutathione S-transferase (GST), HA, green fluorescent protein
(GFP), and red fluorescent protein (RFP)-tagged full-length and truncated
constructs of FGFR2, Grb2, and Plcγ1 were expressed and purified from E.Coli
as previously described (28).
For protein purification, the constructs of interest were transformed into
competent cells. LB media (1 L) with 50 µg/ml antibiotic (ampicillin or
kanamycin) was inoculated with10 ml transformed cells. The culture was grown
to an OD600 cell density of 0.6 at 37°C with constant shaking. The temperature
was dropped down to 20°C before the addition of 300 µM IPTG for the induction
of protein expression. After a 12-h growth period, the cells were harvested by
centrifugation, resuspended in purification buffer (50 mM Tris lysis buffer pH
8.0, 100 mM NaCl, 1 mM β-mercaptoethanol, and protease inhibitors),
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sonicated, and centrifuged (20,000 x g) for 45 min at 4°C. The pellet was
removed, and the filtered supernatant (cleared extract) was applied to an affinity
column equilibrated with purification buffer. Proteins were eluted from the
column with 200 mM imidazole or 20mM glutathione. Concentrated proteins (~5
ml) were applied to an equilibirated Superdex SD75 gel filtration column loaded
with purification buffer. SDS-PAGE analysis was used to detect purity.

Western Blot Analysis, Immunoprecipitation and GST Pull Down
Cultured cells were grown in 10 cm dishes and serum starved overnight. Cells
were either left unstimulated (basal) or stimulated with 20 ng/ml FGF9 (R&D
Systems) for 30 min. Cells were lysed with Hepes lysis buffer (50 mM Hepes,
pH 7.5, 1% [vol/vol] igepal-C630, 1 mg/ml bacitracin, 1 mM EDTA, 10 mM NaF,
1 mM sodium orthovanadate, 10% [vol/vol] glycerol, 50 mM NaCl, 1 mM PMSF,
and Protease Inhibitor Cocktail Set III [EMD Millipore]) as previously described
(2). Protein concentration was quantified by Bradford assay, and 50 µg of total
proteins was used for every blot. For purified proteins, only 10 ng of protein was
utilized for western blot and densitometric analysis via imageJ software (U. S.
National

Institutes

of

Health,

Bethesda,

Maryland,

USA,

http://imagej.nih.gov/ij/), was performed on the blots. Protein A/G Plus-Agarose
(Santa Cruz Biotechnology, Inc) was used for immunoprecipitation experiments.
For GST pull down assays, cleared extract from cells expressing GST-tagged
proteins or empty GST vector that was incubated for 2 h at room temperature
with glutathione sepharose beads that were soaked for 30 min in PBS, washed
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four times with PBS, and then resuspended in Tris buffer. The resultant GSTtagged protein bound to the beads was incubated with cell lysates overnight at
4°C before washing three times with PBS to avoid non-specific binding. This
was followed by western blot analysis to detect protein-protein complex
formation.

Antibodies

were

purchased

from

the

following

sources:

phosphotyrosine (pY99), FGFR2 (C-17), Grb2 (C-23), anti-goat secondary
antibody, and HA-probe (Y-11) (Santa Cruz Biotechnology Inc); anti-GFP (goat)
and anti-RFP (mouse) (Rockland Immunochemicals); β-actin, GST, and antimouse and anti-rabbit secondary antibodies (Cell Signaling Technology); and
THE™ HA-tag (mouse) and Plcγ1 (mouse) (BD Biosciences).
Additional reagents used in experiments were purchased as follows: ATP
competitive FGFR2 inhibitor SU 5402, scrambled shRNA, (catalog no. sc108080), and Grb2 shRNA (catalog no. sc-29335-v) (Santa Cruz Biotechnology,
Inc); phalloidin (catalog. no: 8953) (Cell Signaling Technology); Metafectene
transfection reagent (Biontex-USA); and puromycin dihydrochloride, selection
antibiotic, (Invitrogen).

Cell Fractionation
HEK293T Ci and G2i cells were serum starved overnight. Cells were either left
unstimulated, or stimulated with 20 ng/ml FGF9 for 30 min and then washed
three times with PBS. Cell fractionation was performed using the Subcellular
Protein Fractionation Kit for Cultured Cells (Thermo Scientific). The protein
content in the cytoplasmic and membrane extracts was quantified and analyzed
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by western blot. FGFR2 and β-actin were used to determine the purity of the
membrane and cytoplasmic extracts, respectively.

MTT Assay
A working solution of MTT was prepared by diluting the 5 mg/ml stock solution
(Promega) 1:10 in PBS. Cells were seeded in 12-well plates. The medium was
aspirated and replaced with 40 µl MTT/well. Cells were then incubated for 3 h at
37°C. The MTT dye was solubilized with 1 ml acidic isopropanol (0.04 M HCl),
followed by two 30-min incubation periods in between which the solution was
gently mixed. Finally, the dye solution was transferred to a 1.5 ml eppendorf
tube and centrifuged at 13,000 rpm for 3 min. The supernatant was pipetted into
disposable cuvettes and absorbance was measured at 570 nm with background
wavelength subtraction at 650 nm. Results were plotted using Excel (Microsoft)
and presented as the mean ± standard deviation of the relative fluorescence
units (RFUs) of three independent experiments performed in triplicate.

Surface Plasmon Resonance (SPR)
SPR experiments were performed using a BIAcore T100 instrument with
temperature maintained at 25°C in running buffer (50 mM HEPES, pH 7.5, 100
mM NaCl, and 1 mM β-mercaptoethanol). The CSH3 of Grb2 (Grb2CSH3) was
immobilized to Series S CM4 Sensor Chips to a final level of ~700-900
resonance units (RU) using the manufacturer’s protocol. Synthesized FGFR2
C-terminal peptide (23 amino acids; C23) was diluted in running buffer, and
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binding experiments were performed using a flow rate of 30 µl/min with 180 s
contact time and 300 s dissociation time. Data analysis was performed using
BIAcore evaluation software with data subtraction against blank immobilized,
paired flow-cells.

Fluorescence Microscale Thermophoresis (MST)
MST Experiments were performed using a Monolith NT.115 instrument
(NanoTemper) with temperature maintained at 25°C. The Plcγ SH3 domain was
labeled with primary amine coupling of NT-647 dye according to the
manufacturer’s protocol and purified using Superdex 25 resin in a buffer
containing 50 mM HEPES (pH 7.5), 100 mM NaCl, and 1 mM βmercaptoethanol. Titration series were made using a 1:1 dilution of synthesized
FGFR2 C-terminal peptide (23 amino acids) while maintaining a constant 25 nM
NT-647-labeled Plcγ SH3 domain. Thermophoresis was monitored at four
separate temperature gradients. MST experiments were performed in triplicate
while.

Fluorescence Lifetime Measurement
Fluorescenceresonance energy transfer (FRET) experiments were done to
measure complex formation between Alexa Fluor 488-labeled C58 (emitter) and
Alexa Fluor 555-labeled Plcγ1SH3 (acceptor). In all experiments, 250 µl of
sample was labeled with 10 µM Alexa Fluor (Invitrogen). The sample was then
rotated at room temperature for 1 h before quenching with 40µl Tris-Hcl (pH 8).
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Labeled sample was separated from free dye using a gel filtration column. C58
and Plcγ1SH3 were incubated at an equimolar concentration of 0.5 µM.
Grb2CSH3 concentration was increased sequentially as follows: 0.1 µM, 0.5
µM, and 0.7 µM. Experiments were performed in a spectrofluorometer
(QuantaMaster-4-CW; Photon Technology International) at 23°C in 50 mM TrisHCl, 100 mM NaCl, 1 mM β-mercaptoethanol, and 5% glycerol at pH 8.5. C58
lifetime decay was measured using a pulsed nitrogen laser with an excitation of
488 nm, emission of 510 nm, start delay of 135 ns, and end delay of 150 ns.
200 channels were used with an integration time of 50 µs, 3 averages, 5 shots,
and a frequency of 8 Hz. FeliX32 analysis software (Photon Technology
International) was used to fit the decay curves and compute the lifetime
constants.

Fluorescence Lifetime Imaging Microscopy (FLIM) Analysis
HEK293T cells stably expressing GFP-FGFR2 were transfected with different
RFP-tagged Plcγ1 domains or full length HA-Plcγ1 using Metafectene.
The efficiency of transfection was confirmed using western blot analysis. Serum
starved cells on glass coverslips were either left unstimulated or stimulated with
20 ng/ml of FGF9. Cells were fixed with 4% (wt/vol) paraformaldehyde (pH 8.0)
for 20 min. HA-Plcγ1-transfected cells were fixed, washed with PBS,
permeabilized with 0.5% (vol/vol) Triton X-100, and blocked with blocking buffer
(3% BSA, 0.5% Triton X, and 5% fetal calf serum). Cells were then washed with
PBS and incubated overnight with Alexa Fluor 555-labeledanti-HA antibody (Y-
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11). Cells were washed with PBS and mounted onto a slide with mounting
buffer (0.1% p-phenylenediamine/75% glycerol in PBS). Imaging was
performed using a confocal microscope (model SP5; Leica) at 20°C as
described previously (2). FLIM data was collected with an inverted advanced
confocal microscope system (TCP SP5; Leica) with an internal photomultiplier
tube detector. The samples were excited with a tunable fs titanium-sapphire
pumped laser (Mai Tai BB; Spectra-Physics). Images were acquired with an oilimmersion objective (NA 1.4) and a line scan speed of 400 Hz, with an image
size of 512 × 512 pixels. Pixels used for analysis were 256 x 256. The
fluorescence decays were fitted with a single exponential decay model using
SPCImage software (Becker & Hickl), and the GFP fluorescence lifetimes were
displayed in a false-color histogram. The data shown are representative of three
slides prepared from three independent experiments.

Results
Grb2 inhibits the binding of Plcγ1 to FGFR2
We generated Grb2 shRNA knockdown (G2i) and scrambled shRNA control
(Ci) A431 cells (Fig 2.2a). Immunopreciptiation of Plcγ1 by FGFR2 under nonstimulated conditions showed that the presence of Grb2 in Ci cells inhibited the
association of Plcγ1 with the receptor (Fig 2.2b). Immunoprecipitation of Plcγ1
by FGFR2 (Fig 2.2c) and FGFR2 by Plcγ1 (Fig 2.2d) revealed similar inhibitory
effects in HEK293T Ci cells stably over-expressing FGFR2. A constitutive
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Plcγ1-FGFR2 interaction was observed in G2i cells (Fig 2.2 b,c,d). Therefore,
the Plcγ1-FGFR2 interaction occurred in the Grb2 knockdown background.
a

b

c

d

e
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Fig2.2 Plcγ1 constitutively binds to FGFR2 in the absence of Grb2.a) Grb2
knockdown in A431 G2i cells was confirmed by western blot. A431 cells
transfected with scrambled shRNA were used as a control (Ci cells). Total Plcγ1
and β-actin were used as loading controls.b) A431 and c) Ci (control) and G2i
(Grb2 knockdown) HEK293T cells were serum starved overnight an either left
Unstimulated (basal) or stimulated with FGF9. Cell lysates were obtained and
immunoprecipitation was performed using FGFR2 antibody. The expression of
total FGFR2 and total Plcγ1 in the immunoprecipitates was determined by
western blot. Quantification of western blots was done using ImageJ software
and presented in arbitrary units.d) Lysates obtained from HEK293T Ci and G2i
cells that were unstimulated (basal) or FGF9-stimulated were used for
immunoprecipitation with Plcγ1 antibody.Immunoprecipitates were analyzed for
total Plcγ1 and total FGFR2 by western blot.e) In the absence of Grb2, the
binding of Plcγ1 to FGFR2 does not induce Plcγ1 phosphorylation. HEK293T Ci
and G2i cells were serum starved overnight and either left untreated or treated
with 30 µM SU5402 kinase inhibitor for 2 h. Basal or FGF9-stimulated cell
lysates were obtained and the expression of phosphorylatedPlcγ1 and
phosphorylated FGFR2 was determined by western blot. f) Western blot result
showing the phosphorylation state of Plcγ1 in unstimulated and FGF9stimulated HEK293T cells. Cell lysates from serum-starved Ci, G2i, and G2i
cells with 0.5 µg Grb2 knocked in were obtained, and western blot was done to
determine the expression of phosphorylated Plcγ1, total Plcγ1 (loading control),
and Grb2 (efficiency of knockdown/knock in). g) HEK293T Ci and G2i cells
stably transfected with GFP-tagged FGFR2 were transiently transfected with
HA-Plcγ1. Non-transfected cells were used as controls to detect the initial
lifetime of GFP using FLIM (top row). Constitutive Plcγ1-FGFR2 interaction
does not occur in the presence of Grb2. However, in the absence of
Grb2,Plcγ1-FGFR2 complex formation occurs as evidenced by the reduction in
emission lifetime of GFP (left shift of the peak in graph; right hand column).
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Importantly, Plcγ1 phosphorylation did not occur in HEK293T cells when Plcγ1
was constitutively bound to FGFR2 (Fig 2.2e). FGF9-mediated FGFR2
stimulation induced Plcγ1-FGFR2 complex formation as expected. Under these
conditions,

Grb2

binding

was

abrogated

(1),

FGFR2

was

tyrosine-

phosphorylated, providing a site for the binding of Plcγ1NSH2 (Fig 2.2b,c,d),
and Plcγ1 wasphosphorylated in Ci cells (Fig 2.2e). Knocking Grb2 back into
G2i cells restored Plcγ1 phosphorylation in stimulated cells (Fig 2.2f).

To confirm that the presence of Grb2 affects Plcγ1-FGFR2 complex formation
in a cellular context, we performed FLIM on HEK293T Ci and G2i cells stably
over-expressing

C-terminally

GFP-tagged

FGFR2

(FGFR2-GFP)

and

transfected with HA-Plcγ1 (Fig 2.2g). Fluorescence lifetimes were measured
between GFP and an Alexa Fluor 555 (AF555)-labeled anti-HA-Plcγ1 antibody.
Under non-stimulated conditions in Ci cells, the GFP fluorescence lifetime was
unaffected, suggesting the absence of binding between FGFR2and Plcγ1.
However, in the absence of Grb2, the GFP fluorescence lifetime was
significantly reduced (left shift of lifetime graph; Fig 2.2g). This reduction in
GFP fluorescence lifetime was due to FRET between GFP (donor) and AF555
(acceptor) as the fluorophores approach to within ~10 nm of one another,
suggesting that FGFR2 and Plcγ1 wereclose enough to form a complex.
Stimulation of the receptor resulted in clear protein complex formation through
the well-characterized binding of Plcγ1 to phosphorylated receptor.
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The SH3 domain of Plcγ1 binds to FGFR2
To identify more precisely the FGFR2 site that interacts with Plcγ1, we
performed pull down experiments with truncated polypeptides including the
protein-binding domains of Plcγ1 (Fig 2.3a). Under basal conditions, a GSTtagged polypeptide containing the NSH2, CSH2, and SH3 domains of Plcγ1
(SH223) was able to pull down FGFR2 only in G2i cells (Fig 2.3b). Truncating
the peptide to isolate the SH3 domain was also effective in pulling down the
receptor (Fig 2.3b). We confirmed the interaction between the SH3 domain of
Plcγ1 (Plcγ1SH3) and FGFR2 with additional pull down experiments using
mutant forms of SH223 (Fig 2.3c). R586A and R694A mutants (which disable
NSH2 and CSH2 binding to pY, respectively) and the DM did not abrogate
binding to non-stimulated receptor in G2i cells (Fig 2.3c). This suggested that
the SH3 domain, but not the SH2 domains, of Plcγ1 interacted with the receptor
under non-stimulated conditions.Upon receptor stimulation, Plcγ1-FGFR2
complex formation was observed in R694A SH223-mutated Ci cells, which was
consistent with a previous report demonstrating binding of NSH2 to the
activated receptor (31).
FLIM was also utilized to assess Plcγ1SH3 binding in a cellular context. In
HEK293T cells transfected with GFP-tagged FGFR2 and RFP-tagged
Plcγ1SH3, binding was not observed in Ci cells under non-stimulated
conditions. However, FGFR2-Plcγ1SH3 complex formation did occur in G2i
cells (left shift of lifetime graph compared to isolated RFP; Fig2.3d).
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Therefore, Plcγ1SH3 binding to FGFR2 occurred only in the absence of Grb2.
Similar results were obtained in cells transfected with RFP-tagged SH223 of
Plcγ1 (Fig 2.4a,b,c).

a

	
  

33	
  

Fig 2.3 The SH3 domain of Plcγ1 binds to FGFR2.a) Schematic illustration of
the sequence of Plcγ1 domains. SH223 and SH3 truncated versions shown with
the arginine residues (R586 and R694) that were mutated in SH2 domains to
abrogate binding topY on FGFR2.b) C-terminal GST-tagged polypeptides
SH223-GST, SH3-GST, and GST alone (used as a control) on glutathione
beads were incubated with cell lysates obtained from basal and FGF9stimulated Ci and G2i HEK293T cells. Western blot was used to determine total
FGFR2 and GST expression.c) R586A and R694A mutations were made in the
NSH2 and CSH2 of SH223 of Plcγ1, respectively. R586A and R694A mutants
and DM of SH223 were used for GST pull down assays of basal and FGF9stimulated HEK293T whole cell lysates. d) RFP-tagged Plcγ1SH3 was
transiently transfected in HEK293T cells stably transfected with FGFR2-GFP. Ci
and G2i cells were used for FLIM analysis. Graph (right hand column) shows
distribution of GFP fluorescence lifetime. Complex formation is shown by a
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reduction of the GFP lifetime (left shift of peak). Cells transfected with empty
RFP vector were used as a control (top row).

a

b
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c

Fig 2.4 Plcγ1 binding to FGFR2 is independent of phosphorylation state.a)
Western blot showing the efficiency of transfection of RFP-tagged SH223 and
SH3 constructs in HEK293T control (Ci) and Grb2 knockdown (G2i) cells.Cells
transfected with RFP empty vector were used as a control.b) HEK293T Ci and
G2i cells stably expressing FGFR2-GFP were transfected with SH223-RFP,
serum starved overnight, and treated with FGF9 for 30 min. Cells were washed
and lysed before immunoprecipitation with anti-GFP antibody. Western blot
analysis was done to determine the expression of GFP (as a control) and RFP
to detect the association of FGFR2 with the Plcγ1 SH223 domain.c) Cells
transfected with SH223-RFP or RFP alone were used to detect binding to
FGFR2-GFP by FLIM. Reduced fluorescence lifetime (left shift of peaks in right
hand column) indicates complex formation.
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The C-terminal SH3 domain of Grb2 (Grb2CSH3) binds to a peptide
corresponding to residues 807-821 of the very C-terminus of FGFR2 (2,3). To
determine whether Plcγ1SH3 binds to a similar region on FGFR2, we initially
used a C-terminally GST-tagged 58 residue peptide representing the very Cterminal sequence of FGFR2 (C58; residues 764-821). In a GST pull down
experiment, Plcγ1 was clearly associated with C58 in non-stimulated G2i
HEK293T cells (Fig 2.5a). In an in vitro experiment, C58 was able to pull down
purified Plcγ1; however, this interaction was reduced in the presence of Grb2
(Fig 2.5b).
The Grb2CSH3-FGFR2 interface incorporates a cognate sequence including
proline residues 810 and 813 on the receptor (2). We confirmed that Plcγ1
binds to the same location as Grb2 in pull down assays of HEK293T cell lysates
with C58, in which the binding site was disrupted through mutation of the Cterminal proline residues to alanine (P810A, and P813A; Fig 2.5c). P810A and
P813A mutations, which are in the defined Grb2CSH3 binding site, induced
negligible complex formation in the basal state even in G2i cells. However, in
cells with a proline to alanine mutation (P804A), which is just outside the
structurally determined binding site for Grb2, Plcγ1 was able to bind to C58 in
G2i cells.
To demonstrate that the binding of Plcγ1 is independent of FGFR2
phosphorylation in the non-stimulated state, Y769 on C58-GST was mutated to
phenylalanine (Y769F). Complex formation between C58 and Plcγ1 was
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observed in the absence of pY769 in G2i cells, which indicated that the Plcγ1
and FGFR2 interaction is mediated by Plcγ1SH3 (Fig 2.5d). Conversely, the
ability of C58 to pull down Plcγ1 from Ci cell lysates was limited.
We confirmed the binding between Plcγ1SH3 and the C-terminal (residues 799821; C23) of FGFR2 in vitro using MST. The equilibrium dissociation constant
(Kd) of this interaction was approximately 40 µM (Fig 2.5e). This is similar to the
binding affinity of the second FGFR2 molecule to the Grb2 dimer bound to
FGFR2 in the formation of the FGFR2-Grb2 heterotetramer (Kd ~ 25 µM) (2).
Therefore, it is possible that approximately equimolar concentrations of
Plcγ1SH3 and Grb2 would compete equally for binding to FGFR2 in cells (see
schematic Fig. 2.5f).
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Fig 2.5 Plcγ1 binds to the C-terminus of FGFR2.a) Plcγ1 binds C58 more
effectively in the absence of Grb2. Pull down assays ofcell lysates from basal
and FGF9-stimulated HEK293T Ci and G2i cells with C58 were performed to
determine whether Plcγ1 binds to the C-terminus of FGFR2.Western blot
analysis was done to determine total Plcγ1 and GST expression in the
immunoprecipitates.b) C58 on glutathione beads was incubated with purified
Plcγ1 alone or in combination with Grb2 (equimolar concentration of 10 ng) in a
GSTpull down assay. The expression of Plcγ1, GST, and Grb2 was determined
by western blot and quantitated by densitometric analysis. The histogram
presents the ratio of Plcγ1 to GST following normalization to control cells of 3
independent experiments. Error bars represent standard deviation of the mean
(right panel).c) P804A, P810A, and P813A-mutatedC58 were used in a GST
pull down assay using HEK293T cell lysates. Western blot was done to
determine the expression of total Plcγ1 and GST.d) C58 with a point mutation
Y769F (to which the SH2 domain(s) of Plcγ1 are known to bind) was used in a
GST pull down assay of cell lysates from HEK293T cells,followed by western
blot analysis. The blot was probed for total Plcγ1 and GST. e) MST was used to
measure the binding of C23 to Plcγ1SH3. C23 was titrated with 25 nM NT-647labeled Plcγ1SH3 domain. Binding curve fit to a Kd = 39 µM. f) Schematic
showing the concentration-dependent equilibrium between Grb2 and Plcγ1 for
FGFR2 binding. Top panel: Formation of Grb2-FGFR2 heterotetramer. (1)
Binding of first FGFR2 molecule to Grb2 dimer; Kd = 0.1 µM. (2) Binding of
second FGFR2 molecule to Grb2 dimer; Kd ~ 25 µM. Bottom panel: Competition
between Grb2 and Plcγ1 (only the SH domains are highlighted). (3) Increasing
concentrations of Plcγ1 compete to disrupt the Grb2-FGFR2 heterotetramer (Kd
~ 40 µM). (4) Under high Plcγ1 and/or low Grb2 concentrations, Plcγ1 binding
to FGFR2 will dominate. SH2 – yellow; SH3 domain – red; FGFR2 – blue; Plcγ1
– green.

Plcγ1 and Grb2 compete for binding to FGFR2
The binding of both Grb2 and Plcγ1 via their respective SH3 domains to an
identical region of FGFR2 with similar affinities indicatesthat constitutive Plcγ1
activation relies on a concentration-dependent competition for FGFR2 binding.
To confirm this, an in vitro competition assay using fluorescence spectrometry
was performed to assess whether increasing concentrations of Grb2 could
effectively displace Plcγ1 from FGFR2. C58 was labeled with Alexa Fluor 488
(AF488), and Plcγ1SH3 was labeled with AF555. The fluorescence lifetime of
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AF488-tagged C58 (green arrow; Fig 2.6a) will decrease in the proximity of
AF555 through FRET. Mixing of 0.5 µM of both C58 and PlcγSH3 reduced the
fluorescence lifetime of AF488 (red arrow) due to PlcγSH3 and C58 complex
formation. Subsequent addition of increasing concentrations (0.1-0.7 µM;
maroon arrows) of Grb2CSH3 increased AF488 emission lifetimes as the
unlabeled Grb2CSH3 replaced PlcγSH3 on C58.
Localization to the plasma membrane is fundamental to Plcγ1 phospholipase
lipase function. In the absence of Grb2, a significant concentration of Plcγ1
localizes to the membrane. This was not observed in Ci cells (Fig 2.6b). These
data are consistent with increased concentrations of Plcγ1 being recruited to
the membrane through binding to FGFR2 under non-stimulatory conditions.
In summary, these results show that both proteins are competing for the same
binding site on FGFR2 in a concentration dependent manner. Thus, Plcγ1 will
replace Grb2 on the receptor only in G2i cells under basal non stimulated
conditions.
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Fig 2.6 Plcγ1 and Grb2 compete for binding to FGFR2.a) Fluorescence
spectroscopy measurement of AF555 and AF488-labeled Plcγ1SH3 binding to
C58 in the presence of Grb2CSH3.The green arrow indicates the lifetime
measurement (ns) of C58 (0.5 µM). The red arrow indicates the addition of
Plcγ1SH3 (0.5 µM). The maroon arrows indicate the sequential addition of 0.1,
0.5, and 0.7 µM Grb2CSH3 to the C58 and Plcγ1SH3 mixture. b) Expression of
Plcγ1 in the cellular fractions of HEK293T lysates. Total FGFR2 and β-actin
were used to determine the purity of the membrane (Mem) and cytoplasmic
(Cyto) fractions, respectively.
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Chapter Three: Grb2 and Plcγ1 competition
controls lipase mediated cell migration and
invasion
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Background
When it comes to the activation mechanism of Plcγ1, some features remain
speculative. For example, tyrosine phosphorylation may not always be essential
or adequate for full activation of Plcγ1 (33). However, phosphorylation and X/Y
linker region-mediated intramolecular interactions are required to induce
membrane localization and phospholipase activity (34). Thus, the previously
described SH3-mediated binding of Plcγ1 to FGFR2 might be critical in placing
the lipase in close proximity to its substrate, leading to phosphorylationindependent Plcγ1 activation.
Hydrolysis of the Plcγ1 substrate PIP2 is known to be required for the
development of cellular protrusions, filopodia, and lamellipodia and directional
cell migration (35,36). Plcγ1 activity has been implicated in differentiation, cell
proliferation, chemotaxis, actin remodeling, and cell migration (37-40). Plcγ1
functions are associated with phosphoinositide metabolism, which directly
impacts the actin cytoskeleton (41,42).
Here, we show that SH3-mediated binding of Plcγ1 to FGFR2 under conditions
where the law of mass action favors Plcγ1 over Grb2 (i.e., higher intracellular
concentration of Plcγ1 vs. Grb2) increases Plcγ1 activity and PIP2 hydrolysis,
thereby inducing cellular invasion and metastasis.

	
  

46	
  

Methods
Cells
Human embryonic kidney 293T (HEK293T), and LoVo colon cancer cells were
maintained in Dulbecco’s modified Eagle’s high glucose medium (DMEM),
whereas ROS17/2.8 osteosarcoma cells were grown in phenol red-free DMEM.
DMEM was supplemented with 10% (vol/vol) fetal bovine serum (FBS) and 1%
antibiotic/antimycotic (Lonza) in a humidified incubator at 37°C with 10% CO2.
Grb2 (G2i), and Plcγ1 (Pγi) knockdown cells were generated by infecting cells
Grb2 shRNA and Plcγ1 shRNA lentiviral particles, respectively, followed by
selection with 7 µg/ml puromycin. Controls cells (Ci) were infected with
scrambled shRNA lentiviral particles. Knockdown of Grb2 and Plcγ1 in surviving
cells was confirmed by western blot. Cells were serum starved overnight prior to
stimulation with FGF9 for 30 min.

Western Blot Analysis, and inhibitors
Western blot analysis method is the same as that of the previos chapter.
Antibodies utilized are also mentioned in the “Methods” section of the previous
chapter. Additional reagents used in this part were purchased as follows: Plc
inhibitor U73122 (Sigma Aldrich); and Plcγ1 shRNA (catalog no. sc-29452-v)
(Santa Cruz Biotechnology, Inc); phalloidin (catalog. no: 8953) (Cell Signaling
Technology).

	
  

47	
  

In vitro Plcγ1 Reconstitution Assay to Measure [3H] PI(4,5)P2 Hydrolysis.
Synthetic

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine,

glycero-3-phospho-L-serine,

and

1,2-dioleoyl-sn-

1,2-dioleoyl-sn-glycero-3-phospho-(1'-myo-

inositol-4',5'-bisphosphate) (100 µg of each) (Avanti Polar Lipids) were
combined in chloroform:methanol (2:1) in a molar ratio of 1:1:1 with 0.6 µCi of
[2-3H(N)] PtdIns (4,5)P2 (Perkin Elmer Life Science). Mixed phospholipid
vesicles were created by drying the mixture under vacuum using a Savant
Speed Vac Concentrator, resuspending the dried lipid mixture, and dispersing
on ice by sonication using a probe sonicator at amplitude 15% for 1 min
(Branson Digital Sonifier) in 1 ml of 20 mM Hepes pH 7.4, 20 mM NaCl, 4 mM
EGTA, 8 mM MgCl2, 220 mM KCl, and 0.15 mM CaCl2. Sodium cholate was
added to achieve a final concentration of 0.1% and dissolved by vortexing. To
perform the assay, a radiolabeled substrate was provided as mixed
phospholipid vesicles (100 µl), which were complemented with cholate (as
described above) and combined with an equal volume of cell lysate. The
purified proteins were utilized in experiments to determine enzyme activity and
potential regulation by kinase dead FGFR2, Grb2, and Plcγ1CSH3 (100 µl).
Full-length Plcγ1 was purchased from EMD Millipore. Cell lysates were derived
from HEK293T cells. Assays were performed for 2 h at 37°C and terminated by
the addition of 0.75 ml of chloroform/methanol/HCl (20:40:1), followed by the
addition of 0.25 ml chloroform and 0.25 ml of 0.1 M HCl. Samples were
vigorously vortexed for 1 min and then centrifuged for 1 min.
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Aliquots (100µl) of the upper aqueous (containing the PIP2 hydrolysis product
IP3) and bottom (containing the Plcγ1 substrate PIP2) phases were collected,
dried on GF/F glass microfiber filter, quantitated by liquid scintillation
spectrometry, and normalized to protein concentration. To demonstrate that
other proteins were not involved in the phospholipid turnover in our study,
controls consisting of buffers and purified proteins were assayed for PIP2
turnover (Fig 3.1).

Fig 3.1 Controls for phospholipase in vitro reconstitution assays. The ratio
of [3H]IP3 to [3H]PIP2 was determined and normalized to Plcγ1 plus kinase dead
receptor. Values shown represent the mean ± standard deviation of three
independent experiments.
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Assay of Plcγ1 Activity in Whole Cells
Cellular Plcγ activity was estimated from the measurement of the steady-state
level of PIP2 in [3H]myo-inositol uniformly radiolabelled cells because the PI3K
pathway utilizes only a very small fraction of the PI(4,5)P2 pool compared with
that hydrolyzed by Plc, and the contribution of reutilization of dephosphorylated
[3H]inositol released from PIP2 is negligible (43).
To measure cellular amounts of phosphoinositides, HEK293T cells were prelabeled with myo-[2-3H(N)]inositol (1 µCi/ml) (Perkin-Elmer) for 24 h in inositolfree, FBS-free DMEM medium. Cells were then incubated for 30 min with 20
ng/ml FGF9 and washed with PBS. After labeling, cells were harvested,
washed, and subjected to lipid extraction and thin layer chromatography (TLC)
analysis.

Lipid Extraction and TLC Analysis
Lipid extraction and TLC analysis was performed using the Bligh Dyer method
(44) with some important modifications. The HEK293T cell pellet was
resuspended in 0.2 ml of 0.5 M NaCl in 0.1 M HCl, and then 0.6 ml of
chloroform:methanol (1:2) was added and vigorously vortexed for 30 min. An
additional 0.2 ml of 0.5 M NaCl in 0.1 M HCl was added and vortexed for 10
min. After a 5-min centrifugation in an Eppendorf Table Centrifuge, the upper
water-methanol phase (containing IP3) was discarded, and the lower chloroform
lipid phase (containing PIP2) was carefully transferred to a new eppendorf tube.
The lipid extract (10 ml) was dried on a GF/F glass microfiber filter and counted
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in a scintillation counter. Lipid extracts were immediately analyzed by TLC. To
ensure that the same volumes were used in the TLC analysis, the 25,000 cpm
aliquots were diluted with chloroform when necessary. Prior to silica gel TLC
analysis, PI(4,5)P2 and PI(3,5)P2 were separated by one-dimensional TLC on
potassium oxalate-impregnated silica gel plates using a highly polar solvent
system

containing

chloroform/methanol/ammonium

hydroxide/water

(57:50:4:11, vol/vol/vol/vol) (45). High-performance Partisil LK5 silica gelprecoated TLC plates (20 cm) with a concentration-zone (Whatman Inc. Clifton,
NJ) were impregnated for 1 min in 1.2 % (wt/vol) potassium oxalate in
methanol-water (2:3). After air drying for 15 min, the plates were desiccated at
100°C for 60 min before use. Radiolabeled lipids were visualized and quantified
using a Personal Molecular ImagerTM FX (Bio-Rad Laboratories). Stored
images were processed and quantified using Quantity One software for
scanning

and

analysis

of

the

captured

Phosphor

images

(Bio-Rad

Laboratories). Phospholipid content was expressed as mol% of total
phospholipid based on the pixel intensity of the captured signal on Phosphor
screen generated by the radiolabeled spots on the TLC plate. Phospholipids
were identified based on their retardation factor (Rf) using different
phosphoinositides as standards.

Intracellular Calcium
The intracellular calcium concentration was measured with use of the Fura-2AM
fluorescent indicator. Data was obtained as described previously (46,47).
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Briefly, HEK293T cells were incubated with 5µM Fura-2AM (Calbiochem) at
room temperature for 1 h in the dark and washed with MBSS solution (140mM
NaCl, 5.4mM KCl, 0.5 mM MgCl2, 0.4 mM MgSO4, 3.3 mM NaHCO3, 2 mM
CaCl2, 10 mM HEPES, and 5.5 mM glucose at pH 7.4). Imaging was performed
with use of an InCyt Im Imaging workstation (Intracellular Imaging, Inc.), Nikon
Eclipse TS 100 inverted microscope, and a 12-bit CCD camera (Pixel Fly,
Cooke). Fura-2-loaded cells were excited alternately at 340 and 380 nm, and
the fluorescence emission at 510 nm was measured. The F340/F380 emission
ratio was used as an index of intracellular calcium.
For each experiment, the responses of 20-30 cells were monitored and their
fluorescence emission ratios averaged at the end of recording. Ratios were
converted to an intracellular calcium concentration ([Ca2+]i) using the equation:
[Ca2+]i = Kdβ(R-Rmin)/(Rmax-R), where Kd is the Ca2+ dissociation constant of
Fura-2, β is the ratio of the fluorescence emission intensity of 380 nm excitation
in Ca2+-depleting and Ca2+-saturating conditions, R is the ratio at any time, Rmin
is the minimum ratio in Ca2+-depleting conditions (measured in the presence of
0 mM extracellular Ca

2+

, 5 µM EGTA, and 2 µM ionomycin), and Rmax is the

maximum ratio in Ca2+-saturating conditions (measured in the presence of 10
mM extracellular Ca2+ and 2 µM ionomycin)(51).

Wound Healing Assay
HEK293T Ci, G2i, and Pγi cells were left untreated or transiently transfected
with the appropriate construct. Briefly, cells were seeded into a 12-well plate
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until they reached full confluency. After overnight serum starvation, the surface
of the cells was scratched with a pipette tip. Cells were washed three times with
PBS and then incubated in 1% serum for 6 h with or without U73122 (for Ci and
G2i cells). Images were taken using a confocal microscope (model SP5; Leica)
after 0 h and 6 h. The average distance traveled by the cells between six
arbitrarily chosen points along the wound was quantified in three independent
experiments. The percentage of wound closure was calculated in each
experiment and normalized to that of controls. Values are presented as the
mean ± standard deviation.Differences in the percentage of wound closure
were evaluated using theStudent’s t-test.

Invasion Assay
Matrigel Invasion Chambers in two 24-well plates with 8.0 µm pores were
purchased

from

BD

Biosciences.

Briefly,

cells

were

counted

via

a

hemocytometer using trypan blue to exclude dead cells. Following rehydration
of the chambers, 5 x 104 cells in 0.5 ml serum-free medium were seeded into
the upper chamber. Serum-containing (1%) medium (0.75 ml) was added to the
lower chamber. After incubation for 6 to 24 h in a humidified incubator at 37°C
with 10% CO2, non-invasive cells were scraped off the membrane with cotton
swabs, and invasive cells were fixed and stained using the Hema 3 Stat Pack
(Fisher Scientific). After drying, membranes at the bottom of each chamber
were pealed, mounted onto a slide with mounting buffer (0.1% pphenylenediamine/75% glycerol in PBS), and covered with a glass cover slip.
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Images were taken using a Leica inverted microscope. The number of invasive
cells were counted in four different microscopic fields and are presented as the
mean ± standard deviation of triplicate samples. Differences in the number of
invasive cells were compared using the Student’s t-test. It is important to note
that metastatic LoVo cells exhibit slower growth and migratory properties
compared with HEK293T cells. Also, ROS cells were larger in size and hence,
the number of cells counted per field was lower. Therefore, relative
comparisons of invasion were not performed between cell lines.

Flow Cytometry and Imaging of Actin Polymerization
HEK293T Ci and G2i cells were seeded in 6-well plates at equal confluency.
Serum-starved cells were detached and treated with 1% serum to detect any
early signaling related to changes in actin polymerization. Cells were then
detached again with versene (Lonza), suspended in DMEM, and centrifuged for
5 min at 1000 rpm. The supernatant was aspirated, and the pellet was
suspended in 1 ml of cold PBS. Cells in suspension were then pipetted with
gentle vortexing into 2.5 ml of pure ice cold-ethanol to achieve a final ethanol
concentration of 70%. Suspended cells were incubated at -20°C overnight.
Cells were pelleted at 1500 rpm for 5 min and incubated in 500 µl phalloidin
solution diluted in PBS containing 0.05% Triton X-100, and 0.1 mg/ml RNase
for 60 min at 37°C.The solution was transferred to a 5-ml round bottom
polystyrene tube for flow cytometry. The Gallios Flow Cytometer (Beckman
Coulter) was used. GFP-/phalloidin-, GFP+/phalloidin-, and GFP-/phalloidin+ cells
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were used as controls, and GFP+/phalloidin+ cells were gated. The geometrical
Y-mean value was used as a measure of actin polymerization. Values were
normalized to control cells and presented as the mean ±standard deviation of
triplicate samples.
For actin imaging, detached cells in 1% serum on coverslips were fixed with
paraformaldehyde, permeabilized, blocked as previously described, and treated
with Hoescht for 15 min at a dilution of 1:10,000. Cells were then washed with
PBS, incubated with phalloidin solution, mounted onto coverslips, and imaged
using aconfocal microscope (model SP5; Leica).

Data Base Analysis
All analyses were performed in R (version 3.0.1) (http:///www.r-project.org/).
Clinical information was downloaded, and CEL (Affymetrix U133Plus2) array
files supplied with the paper from reference 48. justRMA was used to compute
expression values.
Clinical information and level2 Affymetrix (Affymetrix U133 Array Plate Set)
gene expression data publicly available from the Cancer Genome Atlas Project
(TCGA; http://tcga-data.nci.nih.gov/) for ovarian serous cystadenocarcinoma
were also downloaded. Homogeneity between cohorts is important for valid
comparisons. Therefore, tumors of low malignant potential, non-serous tumors,
and tumors other than ovarian or peritoneum were excluded. Samples from
patients who received chemotherapy were also excluded.
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For

each

cohort

(TCGA,

reference

48),

the

relationship

between

FGFR2/Plcγ1/Grb2 expression and overall survival was evaluated. To do this,
patients were grouped into percentiles according to mRNA expression. The
Log-rank test was employed to determine the association between mRNA
expression and survival, and the Kaplan-Meyer method was used to generate
survival curves. Cut-off points to significantly split (log-rank test p-value <0.05)
the samples into low/high mRNA groups were recorded. The cut-off to optimally
separate the patients in both data sets (smallest p-value in each of the cases)
was chosen. In each cohort, we added second and third expression levels to
gain further insight into the association between FGFR2/Plcγ1/Grb2 expression
and overall survival.Therefore,in the second expression level, the cohort was
divided into four groups according to low/high gene1 expression and low/high
gene2 expression.To do this,the optimal cut-off levels for gene1 and gene2
were determined as described above.Survival rates between the low
FGFR2/high Plcγ1 and high FGFR2/low Plcγ1 groups were compared with the
low FGRF2/low Plcγ1 and high FGRF2/high Plcγ1. Similar comparisons were
made for the FGFR2/Grb2 groups. Larger differences in median survival times
were observed when the expression levels of two genes was included in the
analysis instead of single gene expression. Furthermore, significantly larger
differences in median survival times were observed with the addition of the third
expression level compared with the second expression level.
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Results
Competition between Plcγ1 and Grb2 dictates signaling response
To demonstrate the competition between Grb2 and Plcγ1 in non-stimulated
conditions, HEK293T Ci and G2i cells were transfected with 0.5 µg of HA-Plcγ1
or left untransfected (Fig 3.2a) and serum starved overnight. Cell lysates were
obtained and incubated with radioactive substrate either for 2 h (Fig 3.2b) or
overnight (Fig 3.2c). In Ci cells, an increase in Plcγ1 lipase activity was
observed with increased Plcγ1 expression, suggesting that Plcγ1 can displace
Grb2 from FGFR2 binding (Fig 3.2b). Increased expression of Plcγ1 in the
absence of Grb2 also increased phosphoinositide turnover, presumably due to
the additional availability of FGFR2 for complex formation with Plcγ1.
In a similar experiment, the competitive binding between Plcγ1 and Grb2 was
demonstrated under non-stimulated conditions in Grb2-overexpressing cells
(Fig 3.2c). As expected from previous experiments, G2i cells showed elevated
IP3 production compared with Ci cells (Fig 3.2d). Increasing the expression of
Grb2 (0.5 µg and 1 µg plasmid) in G2i cells resulted in Grb2-mediated
displacement of Plcγ1 bound to FGFR2 with a concomitant reduction in IP3:
PIP2

ratio.

These

findings

highlight

that

the

concentration-dependent

competition between Grb2 and Plcγ1 for FGFR2 binding controls basal cellular
phospholipase activity.
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Fig 3.2 Competition between Plcγ1 and Grb2 dictates signaling response.
a) HEK293T Ci and G2i cells were either left untransfected or transfected with
0.5 µg of Plcγ1 and serum starved overnight. Cell lysates were obtained,
andthe expression of total Plcγ1 and β-actin (loading control) was determined
by western blot. b) Phospholipase assay was done to determine the ratio of
[3H]IP3 to [3H]Ptldlns(4,5)P2 (PIP2) in untransfected and HA-Plcγ1-transfected
HEK293T Ci and G2i cells. Cells were incubated with [3H]Ptldlns(4,5)P2
substrate for 2 h. Values shown represent the mean ± standard deviation of
three independent experiments.c) Phospholipase assay was performed on
untransfected and HA-Plcγ1-transfected serum-starved HEK293T Ci and G2i
cells that were incubated with [3H]Ptldlns(4,5)P2substrate for 24 h.The ratio of
[3H]IP3 to [3H]Ptldlns(4,5)P2 was calculated after scintillation counting. Values
shown represent the mean ± standard deviation of three independent
experiments. d) Serum-starved HEK293T Ci cells were left untransfected
andG2i cells were either untransfected or transfected with increasing amounts
of myc-tagged Grb2 (0.5 µg and 1 µg). Cell lysates were obtained and western
blot analysis was performed to determine the expression of Grb2 and the
loading controls total Plcγ1 and β-actin.e) Grb2 downregulates Plcγ1 activity.
Cellular phospholipase assay was used to determine the activity of Plcγ1 in
untransfected and myc-Grb2-transfected G2i HEK293T cells (0.5 µg and 1 µg).
Five independent measurements were made for each experiment. The data
was normalized to control cells, and normalized data were used to calculate the
standard deviation.
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Plcγ1 is constitutively active upon FGFR2 binding
To establish whether Plcγ1 recruitment to FGFR2 is sufficient to promote
enzyme activity, the steady-state level of PIP2 substrate was determined in
HEK293T Ci and G2i cells. To do this, cells were incubated overnight under
serum starvation conditions with radioactive myo-[2-3H] inositol. Lipids were
extracted, separated, and identified by TLC. Quantification of TLC bands
showed that PIP2 concentration was ~50% lower in G2i cells compared with Ci
cells (Fig 3.3a). Therefore, a higher concentration of PIP2 was turned over in
the absence of Grb2 under non-stimulated conditions. We confirmed this
observation by measuring phosphoinositide turnover in total cell lysates of
equal protein concentration prepared from Ci and G2i cells incubated with
radiolabeled PIP2 for 2 h. After phase separation, the IP3 product and remaining
PIP2 substrate were quantified using scintillation counting, and the IP3 to PIP2
ratio was calculated (Table 3.1). In the G2i background, a dramatic increase in
phospholipase activity as measured by PIP2 turnover was observed in the nonstimulated state (Fig 3.3b).
Further confirmation of the constitutive upregulation of Plcγ1 activity in the
absence of Grb2 was provided by the dramatic increases in basal [Ca2+]i and
F340/F380 emission ratio in G2i cells compared with Ci cells (Fig 3.3c). Basal
[Ca2+]i was increased approximately five-fold and 2.5-fold in G2i cells compared
with Ci cells, respectively ([Ca2+]i,~55 nM vs. ~250 nM; F340/F380 ratio, 0.2 vs.
0.5; Fig 3.3d). Addition of ionomycin (a Ca2+ ionophore) resulted in the
expected increase in calcium concentration, which confirmed that the cells were
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functional (see arrows Fig 3.3c,e). The low [Ca2+]I in parental HEK293T cells,
which have negligible FGFR2 expression, demonstrated that the increasein
Plcγ1 activity was due to FGFR2 recruitment and not to non-specific binding to
the lipid membrane (Fig 3.3e,f,g). Furthermore, overexpression of HA-Plcγ1 in
parental cells failed to increase [Ca2+]i to the levels observed in the presence of
FGFR2 in G2i cells (Fig3.3e,f).

	
  

61	
  

a

b

c

	
  

62	
  

d

e

	
  

63	
  

f

g
	
  
	
  

Fig 3.3 Plcγ1 is constitutively active in the absence of Grb2.a) HEK293T Ci
and G2i cells were labeled with radioactive myo-[2-3H]inositol overnight and
then serum starved. Cells were left untreated or stimulated with FGF9. Lipids
were extracted, separated by TLC, and PIP2 and PIP3 were identified. PIP2
bands are shown. b) HEK293T Ci and G2i cells were loaded with Fura 2-AM.
[Ca2+]i, and F340/F380 emission ratio were plotted after calibrating the
measurements to detect their specificity and sensitivity for Fura 2-AM.
Ionomycin was added to detect effective transfer of Ca2+ across cell
membranes. Arrows indicate the timepoint of ionomycin addition. c) [Ca2+]i and
F340/F380 emission ratio were determined from 0 to 2 min in Ci and G2i cells.
Values shown represent the mean ± standard deviation of three independent
experiments.*Student’s t-test (p value ≤ 0.05). d) Parental HEK293T cells,
which have low endogenous FGFR2 expression, were left untreated or
transfected with 0.5 µg of Plcγ1. Cells were loaded with Fura 2-AM, and [Ca2+]i
and F340/F380 ratio were plotted. Arrows indicate the timepoint of ionomycin
addition. e) [Ca2+]i and F340/F380 ratio from 0 to 2 minutes were determined in
parental cells. Values shown represent the mean ± standard deviation of three
independent experiments. f) Western blot was performed on cell lysates from Ci
cells and parental HEK293T cells to show the negligible level of FGFR2
expression in parental cells (upper panel). g) Western blot showing the
efficiency of HA-Plcγ1 transfection in serum-starved parental cells (lower
panel). The expression of total FGFR2, total Plcγ1, and β-actin in f) and g) was
determined in non-transfected and HA-Plcγ1-transfected parental cells.
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Table 3.1 Examples of the upper phase and lower phase counts (prior to
averaging) from the 2-h lipase assay in a) cell lysates and b) purified
proteins. The calculated ratio of [3H]IP3 to [3H]Ptldlns(4,5)P2and [3H]IP3 release
in pmol are shown. [3H]IP3 release was calculated based on the initial cpm value
of substrate used and converted to pmol: (cpm of [3H] IP3 x 7.5)/4415.
Grb2 knockdown results in Plcγ1 recruitment to FGFR2 and positively regulates
Plcγ1 activity in the non-stimulated state. We showed that these events are
mutually dependent by adopting an in vitro reconstitution assay to assess
whether the binding of isolated Plcγ1 to FGFR2 can activate phospholipase
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PIP2 turnover in the presence and absence of Grb2. To ensure that the receptor
and Plcγ1 remained unphosphorylated, a kinase dead FGFR2 (FGFR2KD) was
generated by K517I point mutation. Unphosphorylated Plcγ1 and FGFR2KD (10
µM) were incubated for 2 h with radioactive PIP2, and the ratio of IP3 to PIP2
was calculated (Fig 3.4a). In the presence of FGFR2KD, Plcγ1 exhibited a high
level of in vitro phospholipase activity. Addition of either Grb2 or Grb2CSH3 to
the Plcγ1 and FGFR2KD mixture significantly reduced phospholipase activity
(Fig

3.4a).This

strongly

suggested

that

the

binding

of

Plcγ1

to

unphosphorylated FGFR2 is sufficient to upregulate phospholipase activity and
that Grb2 inhibits this interaction.
To show that the increase in phospholipase activity is independent of Plcγ1
phosphorylation, lipid turnover was measured in two Plcγ1 mutants: Plcγ1TM,
all tyrosines in the X/Y linker region (Y771F, Y775F, Y783F) and C-terminal
(Y977F, Y1253F) were mutated to phenylalanine (Fig 3.4b) and Plcγ1DM, both
SH2 domains were disabled with R586A and R694A mutations (Fig 3.4b).
Overexpression of both Plcγ1TM and Plcγ1DM increased phospholipase
activity (Fig 3.4c).
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Fig 3.4 Plcγ1 SH3-mediated phospholipase activity is concentration
dependent and phosphorylation independent. a) In vitro reconstitution assay
showing the inhibitory effect of full-length Grb2 andGrb2CSH2 on Plcγ1 activity.
The ratio of [3H]IP3 to [3H]PIP2 was computed, and values shown represent the
mean ± standard deviation of three independent experiments. *Student’s t-test
(p value ≤ 0.05). Insert: Western blot demonstrating that the Plcγ1 used in these
experiments was unphosphorylated (left lane). Incubation of Plcγ1 with the
cytoplasmic portion of FGFR2, ATP, and MgCl2 induced Plcγ1 phosphorylation positive control (right lane). The blot was probed with anti-pY (showing
phosphorylated protein; lower panel) and anti-Plcγ1.b) Plcγ1 is active in the
absence of phosphorylation and intramolecular SH2 domain interactions. Five
point mutations where made in full-length HA-Plcγ1 (Y771F, Y775F, Y783F,
Y977F, and Y1253F; TM; http://www.phosphosite.org). Two point mutations
were made in the CSH2 and NSH2 of full-length HA-Plcγ1 (R586A and R694A;
DM). Serum-starved HEK 293T cells were transiently transfected with DM, TM,
or left untransfected (NT). Western blot analysis was done to detect the
efficiency of transfection. The membrane was probed with the following
antibodies: anti-HA, anti-total Plcγ1, and anti-β-actin (loading control). c)
Cellular lipase assay was performed on cell lysates obtained from
untransfected, DM-transfected, and TM-transfected serum-starved HEK293T
cells. [3H]IP3 to [3H]Ptldlns(4,5)P2 ratios were normalized tocontrol cells. Error
bars represent the standard deviation. Both TM and DM are able to turnover
lipid. Elevated concentrations of the Plcγ1 mutants are capable of outcompeting
endogenous Grb2 for binding to FGFR2. In G2i cells, the difference in lipid
turnover was less dramatic, presumably because the competition for FGFR2
binding is reduced in the absence of Grb2.
Competition between Plcγ1 and Grb2 dictates cell migration and invasion
Previous reports have demonstrated that upregulation of Plcγ1 activity
increases cellular motility and metastasis (17). Grb2 and Plcγ1 compete for
binding to FGFR2; therefore, in situations where the respective concentrations
of the proteins favor Plcγ1 binding, we would expect an increase in cell motility
and invasion. We used a wound healing assay to investigate the physiological
outcome of the competition between Plcγ1 and Grb2 for FGFR binding. Motility
was increased in G2i basal cells compared with Ci basal cells (Fig 3.5a,b). A
dramatic increase in cell motility in the absence of Grb2 was observed by
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monitoring the wound healing assay over a 24-h period using time lapse
microscopy (videos are not included in this report). Our findings are consistent
with previous reports demonstrating that upregulation of Plcγ1 phospholipase
activity in the absence of Grb2 increases cell motility by increasing cellular
calcium concentrations (14,49,50). To demonstrate that the competition
between Plcγ1 and Grb2 dictates cell migration response, we overexpressed
Plcγ1DM in Ci cells. Plcγ1DM is incapable of binding to pY on FGFR2 and, thus
any effect of Plcγ1 activity will be due to SH3-mediated recruitment. Cell motility
and [Ca2+]i were greater in Plcγ1DM Ci cells than in untransfected Ci cells (Fig
3.5c,d,e,f). MTT assay confirmed that cell viability was unaffected by
transfection of DM (Fig 3.5 g). Ci and G2i cells treated with the phospholipase
inhibitor U73122 and HEK293T Pyi cells stably overexpressing FGFR2 induced
negligible wound healing capability (Fig 3.5 h,i), confirming that the observed
wound healing was due to Plcγ1. Also, MTT assay demonstrated that the
observed wound healing was not due to reduced cell viability (Fig 3.5 j). Plcγ1
knockdown in Pyi cells was confirmed by western blot (Fig 3.5 k).
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Fig 3.5 Plcγ1 activity increases cell motility in the absence of Grb2. a)
Wound healing assays were performed in triplicate on HEK293T Ci and G2i
cells treated with 1% serum for 6h. Images were taken at the beginning of the
experiment (0 h) and at 6 h. b) Distance traveled by HEK293T Ci and G2i cells
was quantified in three independent experiments. The percentage of wound
closure was calculated, averaged, and normalized against control cells. Values
shown represent the mean ± standard deviation. *Student’s t-test (p value ≤
0.01).c) Untransfected and DM-transfected Ci cells were used in a scratch
wound healing assay. Cells were treated with 1% serum. Images were taken at
0 h and 6 h. d) The percentage of wound closure was measured, averaged, and
normalized against control cells. Values shown represent the mean ± standard
deviation of three independent experiments. e) DM-transfected HEK293T Ci
cells were loaded with Fura 2-AM in Hanks’ buffer, and basal calcium release
was determined by measuring [Ca2+]i and F340/380 emission ratios. Ionomycin
was added to detect effective transfer of Ca2+ across cell membranes. Arrows
indicate the time ofionomycin addition. f) Calcium release was compared
between untransfected and DM-transfectedHEK293T Ci cells. Calcium release
was determined by measuring [Ca2+]i and F340/380 emission ratiofrom 0 to 2
min. Values shown represent the mean ± standard deviation of three
independent experiments. g) MTT assay was performed on untransfected and
DM-transfected Ci cells. Values shown represent the mean ± standard deviation
ofthreeindependent experiments. h) Wound healing assay was performed on
HEK293T Ci and G2i cells treated with 1% serum containing 9 µM U73122 and
Plcγ1 knockdown (Pγi) cells. Images were taken at the beginning of the
experiment and at 6 hours.i) Distance traveled by untreated and U73122treated cells was quantified, and the normalized percentage of wound closure
was calculated. Values shown represent the mean ±standard deviation of three
independent experiments.j) MTT assays were performed to demonstrate the
lack of effect of Grb2 and Plcγ1 knockdown, scrambled shRNA transfection,
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and U73122 treatment on cell viability.k) Western blot showing the efficiency of
Grb2 and Plcγ1 knockdown in G2i and Pyi HEK293T cells, respectively.

We also determined whether the competition between Plcγ1 and Grb2 affects
cell invasion properties (Fig 3.6a,b). At 6 and 24 h, G2i cells had an increased
invasive capacity compared with Ci cells. This can be specifically attributed to
Grb2

knockdown

because

invasion

decreased

with

increasing

Grb2concentrations in HEK293T cells (Fig 3.6c,d). Similar results were
obtained in LoVo metastatic human colon adenocarcinoma cells, which express
low levels of Grb2 and high levels of FGFR2 (top panel, Fig 3.6g) (51). After 24
h in the presence of increasing concentrations of Grb2, the number of invaded
LoVo cells was reduced (Fig 3.6c,d,e).
The inhibitory effect of Grb2 on invasion was further confirmed in Ci and G2i
cells generated from the Rat osteosarcoma ROS17/2.8cell line, which
expresses endogenous levels of FGFR2 (Fig 3.6h). Inhibition of Plcγ1 by
U73122 treatment or knockdown decreased the invasive ability of HEK293T,
LoVo, and ROS cells (Fig 3.6f,i). Downregulation of Plcγ1 expression in LoVo
and ROS Pyi cells was confirmed by western blot (Fig3.6g[bottom panel],h)
The inhibitory effect of Plcγ1 downregulation was not due to decreased cell
viability as confirmed by MTT assay (Fig 3.6j).
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Fig 3.6 Plcγ1 activity increases invasive behavior in the absence of
Grb2.a) Matrigel invasion assays were used to determine whether the
competition between Plcγ1 and Grb2 dictates invasion. HEK293T Ci and G2i
cells were placed in the upper chamber in serum starvation medium, and 1%
serum was placed in the lower chamber. Images were taken after 6 h and 24 h.
G2i cells are more invasive than Ci cells at both timepoints. b) The number of
invasive cells was counted in four microscopic fields for each sample. Values
shown represent the mean ± standard deviation of triplicate samples.c)
Invasion assay was performed on HEK293T G2iand LoVo cells transfected with
increasing concentrations of Grb2 (0.5 µg and 1 µg). Images were taken after
24h. G2i (left) and LoVo (right) cells transfected with 0.5 and 1 µg Grb2. d) The
number of invasive cells was counted in 4 microscopic fields. Values shown
represent the mean ± standard deviation of triplicate samples.e) LoVo cells
were left untransfected or transfected with myc-tagged Grb2 (0.5 µg, and 1 µg).
Cells were serum starved overnight. Cell lysates were obtained, and the
efficiency of Grb2 transfection was determined by western blot analysis. Total
Plcγ1 and tubulin were used as loading controls. f) (Top panel) Invasion assays
were performed on Ci, G2i, and Pγi HEK293T;Ci, G2i, and Pγi ROS cells; and
Ci and Pγi LoVo cells. LoVo cells have a relatively low level of endogenous
Grb2 expression. (Middle panel) Invasion assays were performed on untreated
U73122-treated HEK293T and ROS Ci and G2i cells. U73122 wasadded tothe
upper and lower chambers ata final concentration of 9 µM. (Bottom
panel)Invasion assays were performed on LoVo cells (untransfected with
shRNA)that were left untreated or treated with U73122. In all cases, cells were
incubated for 24 h, fixed, stained, mounted onto microscopic slides, and imaged
at 20X magnification.g) (Top panel)Western blot was performed to determine
total Plcγ1 and Grb2 expression incell lysates obtained from serum-starved
HEK293T Ci and G2i cells and LoVo cells. β-actin was used as loading
control.(Middle panel)Western blot results showing the efficiency of Plcγ1
knockdown in LoVo Pyi cells. The membrane was probed for total Plcγ1, Grb2,
and β-actin. h) Western blot showing the efficiency of Grb2 and Plcγ1
knockdown in ROS G2i and Pyi cells, respectively. Ci cells were used as
controls. The membrane was probed for total Plcγ1, Grb2, and β-actin.i) The
number of invasive cells was counted in four microscopic fields and presented
as the mean ± standard deviation of triplicate samples.j) MTT assays were
performed to confirm that the inhibitory effects of Grb2 and Plcγ1
downregulation were not due to adverse effects oncell viability. Values are
expressed as relative fluorescent units (RFUs) and presented as the mean ±
standard deviation of three independent measurements.
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To test whether the Plcγ1-dependent invasive potential requires FGFR2,
parental HEK293T cells, in which FGFR2 expression is negligible, were
transfected with scrambled shRNA, Grb2 shRNA, and Plcγ1 shRNA to generate
PCi, PG2i, and PPYi cell lines, respectively (Fig 3.7a). After 24 h, PPYi cells
exhibited limited invasive ability (Fig 3.7b,c) compared with PG2i cells. Cell
viability was confirmed by MTT assay (Fig 3.7d).
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Fig 3.7 Invasive behavior in cells is FGFR2 dependent. a) HEK293T
parental cells, which express low levels of FGFR2 were used to generate stable
Grb2 (PG2i) and Plcγ1 (PPγi) knockdowns. Cells transfected with scrambled
shRNA (PCi) were used as a control. Western blot analysis was done to
determine the efficiency of the Grb2 and Plcγ1knockdown. β-actin was used as
a loading control. b) PCi, PG2i, and PPγi cells were used in a 24-h invasion
assay. c) The number of invasive PCi, PG2i, and PPγi cells was counted in four
microscopic fields and presented as the mean ± standard deviation of three
independent experiments performed in triplicate. d) Cell viability of PCi, PG2i,
and PPγi cells was determined by MTT assay. Data shown represent the mean
±standard deviation of three independent experiments.

Next, we evaluated the effect of Plcγ1 on morphological changes associated
with invasive behavior, including actin polymerization. Changes in the actin
cytoskeleton precede cell migration and invasion. Therefore, phalloidin staining
was used to detect changes in actin polymerization in HA-Plcγ1-transfected Ci
and G2i cells. Under basal conditions, Plcγ1 was localized on migratory
structures in G2i cells compared withCi cells (Fig 3.8a). Furthermore, G2i cells
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were larger and had more spread cell morphology and extensions compared
with Ci cells (Fig 3.8b).
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Fig 3.8 Plcγ1 localizes on migratory structures in G2i cells. a) HEK293T Ci
and G2i cells stably expressing FGFR2-GFP were transiently transfected with
HA-Plcγ1. Serum-starved cells were treated with Alexa Fluor 555-labeled HAantibody.Microscopy was used to detect Plcγ1 and FGFR2 colocalization
(yellow).High magnification view of Plcγ1 and FGFR2 colocalization on
migratory structures (lower far right panel). b) HEK293T Ci and G2i cells were
detached and treated with 1% serum for 2 h. Cells were stained with phalloidin
to detect actin polymerization and counterstained with Hoechst (nuclear stain).
Actin polymerization was induced in G2i, but not Ci, cells as evidenced by
phalloidin staining intensity and morphological changes.

Flow cytometric analysis further confirmed the induction of actin polymerization
by Plcγ1 activation in the absence of Grb2. Cells with both GFP and phalloidin
were counted in Ci and G2i (knockdown cells) samples (Fig 3.9a,b). Following
quantification and normalization to Ci cells, a ~36% increase in actin
polymerization was observed in G2i cells (Fig 3.9c).
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c

Fig 3.9 Actin polymerization is higher in G2i cells compared withCi cells.
a), b) HEK293T Ci and G2i cells were treated with 1% serum for 2 h,counted,
fixed, and stained with phalloidin. Flow cytometricanalysis of phalloidin staining
was doneto quantify actin polymerization. c) Flow cytometry data was
normalized to Ci cells and presented as the mean ±standard deviation of three
independent experiments.
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Plcγ1 and Grb2 expression influence survival outcome in ovarian cancer
patients
Having shown that Plcγ1 and Grb2 competition for FGFR2 binding dictate cell
invasion and migration, we next investigated the effect of this competition on
the survival outcome of cancer patients. Kaplan-Meier survival curves
generated from ovarian cancer patients revealed that high level of FGFR2/Plcγ1
was associated with worse survival compared with low level of FGFR2/Plcγ1,
respectively. Also, high Grb2 /low FGFR2 /low Plcγ1 level profile was
associated with better survival in ovarian cancer patients compared to low Grb2
/high FGFR2 /high Plcγ1 level profile (Fig 3.10).
In summary, Plcγ1 binding to FGFR2 when the Grb2 concentration is low
increases cell motility and invasion, which are prerequisites to metastasis.
Therefore, Grb2 and Plcγ1 protein concentrations may dictate metastatic
potential, which may impact patient survival outcome.
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Fig 3.10 High Grb2 and low FGFR2 and Plcγ1 expression profile is
associated with better survival in ovarian cancer. Data from online TCGA
and Tothill databases was used to generate Kaplan-Meier overall survival (OS)
curves of patients with ovarian cancer. mRNA levels of FGFR2, Plcγ1, and
Grb2 (presented individually or in different combinations) were determined from
microarray studies. Cut-off values and statistical significance determined by
Student’s t-test are shown for each survival curve.
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Chapter Four: PTEN-mediated Akt activation is
dictated by Grb2 expression level
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Background
The Akt pathway is an important oncogenic pathway that promotes cell growth,
survival, and glucose metabolism (22). The activity of this pathway is dependent
on plasma membrane phospholipid constituents. Class I PI3Ks phosphorylate
plasma membrane-localized PIP2 to produce PIP3. PIP3 binds to Akt to induce
Akt activation (52,53). Akt activity is counteracted by PTEN, a lipid phosphatase
that hydrolyzes PIP3 to PIP2 (54,55). The balance of PI3K and PTEN activity in
controlling the abundance of phospholipids is important in cellular response.
It is important to note that PTEN activation is only possible in the presence of a
subset of PIPs such as PIP and PIP2. Recent studies have established that the
binding of PIP2 to the N-terminus of PTEN (56) induces a conformational
change (18) that upregulates phosphatase activity (57). PTEN phosphorylation
leads to a closed conformation that inhibits phosphatase activity (58).
In the previous chapters, the expression level of Grb2 in cells was shown to
have a profound effect on Plcγ1 activity in non-stimulated cells. In cells depleted
of Grb2 (G2i cells), Plcγ1 binding to FGFR2 results in Plcγ1 activation and
subsequent PIP2 turnover.
In this chapter, Plcγ1-mediated reduction in PIP2 concentration due to depleted
Grb2 concentration is shown to down-regulate PTEN activity, resulting in PIP3
accumulation. This leads to membrane-recruitment and activation of the Akt
signaling pathway, which enhances cell proliferation (Fig 4.1). Thus, fluctuations
in the concentrations of two competing non-phosphorylated proteins via their
SH3

	
  

domains

can

affect

cell

fate

by

modulating

PIP2

level.

101	
  

Fig 4.1 Basal stage competition between Grb2 and Plcγ1 controls PTENmediated Akt activation. (top) In cells with high levels of Grb2, Plcγ1 is unable
to bind to FGFR2 and thus, membrane-localized PIP2 is not depleted. PIP2
stabilizes PTEN activity. (bottom) In the absence of Grb2, Plcγ1 is able to bind
to FGFR2. Activated Plcγ1 hydrolyzes PIP2. Depletion of PIP2 destabilizes
PTEN activity. Loss of PTEN function leads to the accumulation of PIP3, which
binds to Akt to increase its phosphorylation and activity.
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Methods
Reagents
FGFR2 (C-17) and Grb2 (C-23) antibody and scrambled shRNA, Grb2 shRNA,
and Plcγ1 shRNAs were purchased from Santa Cruz Biotechnology. Anti-GFP
and

anti-RFP

Immunochemicals.

rabbit

antibodies

U0126

were

(MEK1/2

purchased

inhibitor),

from

Rockland

phospho(Ser241)-PDK1,

wortmannin (PI3K inhibitor), β-actin antibody, anti-mouse and anti-rabbit
secondary antibodies, Akt, phospho(Ser473)-Akt, phospho(Thr308)-Akt, phosphoPTEN, and phospho(Ser21/9)-GSK-3α/β (37F11) were purchased from Cell
Signaling Technology. Plcγ1 mouse antibody was purchased from BD
Biosciences. Puromycin dihydrochloride, selection antibiotic, was purchased
from Invitrogen. Metafectene transfection reagent was purchased from BiontexUSA. The Plc inhibitor U73122 was purchased from Sigma-Aldrich. The PTEN
inhibitor SF 1670 was purchased from Echelon Biosciences.

Cell culture
Parental and FGFR2-overexpressing HEK293T cells were cultured in DMEM
supplemented with 10% (vol/vol) FBS and 1% antibiotic/antimycotic (Lonza) in a
humidified incubator at 37°C with 10% CO2. Ci, G2i, and Pγi cells were
established as described in Chapter Two.
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Western Blot Analysis
Cultured cells were grown in 10-cm dishes and serum starved overnight. Cells
were left untreated or treated with 9 µM U73122, 1 µm wortmannin, or 10 µM
U0126 for 2 h. Cells were also treated with 500 nM SF 1670 for 30 min. Cells
were lysed with Hepes lysis buffer (50 mM Hepes, pH 7.5, 1% [vol/vol] igepalC630, 1 mg/ml bacitracin, 1 mM EDTA, 10 mM NaF, 1 mM sodium
orthovanadate, 10% [vol/vol] glycerol, 50 mM NaCl, 1 mM PMSF, and Protease
Inhibitor Cocktail Set III (EMD Millipore) . Protein concentration was quantified
at 595 nm, and 50 µg of total proteins was used for every blot.

Kinase Assay
Cell lysates were collected and incubated with total Akt antibody overnight.
Protein A/G Plus-Agarose (Santa Cruz Biotechnology) was used for
immunoprecipitation experiments according to the manufacturer’s instructions.
Cell lysate bound to immobilized antibody waswashed with 3x lysis buffer ,
suspended in 50µl 1x kinase buffer (Cell Signaling Technology), and incubated
with 10 mM ATP (1 µl)and Akt substrate (1 µl;purified GSK-3 fusion protein [Cell
Signaling Technology]) for 30 min at 30°C.The reaction was terminated by
adding sample loading buffer and heating the samples. Samples (20 µl) were
loaded onto a gel and subjected to western blot analysis.
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Soft Agar Assay
One milliliter of 1% FBS DMEM containing 0.75% agar was used as the bottom
layer. 0.6 x104 of indicated cells were cast in agar as a single cell suspension in
1 ml DMEM (upper layer). Cells were left to grow for 8 days. 500 ml of DMEM
with 1% FBS (with or without inhibitors (4 µM U73122/100 nM Wortmannin/5
µM U0126/150 nM SF 1670) was added to the wells once a week.
Drugs of interest were added to the underlay and overlay agar medium, as well
as the liquid top layer which was initiated one day after seeding the cells.
Concentrations were optimized so as to avoid cell death over the prolonged
period of 8 days. Every experiment was performed in triplicates. Colonies were
counted and averaged in different microscopic fields then normalized against
control cells in serum starvation medium. Error bars on the graph represent the
standard deviation calculated.

Phosphatase Assay
PIP2 and Ptdser (both from Avanti Polar Lipids,INC) were prepared to a final
concentration of 2 mg/ml and 5 mg/ml respectively in chloroform:methanol:
10mM HCl (20:9:1). The resuspension buffer was composed of 20 mM HEPES
(pH 7.5), 1mM MgCl2, and 1 mM EGTA. Kinase buffer consisted of 400 mM
HEPES (pH 7.8), 100mM MgCl2, and 20 mM EGTA.
For substrate preparation, 16.8 µl PIP2 stock and 6 µl Ptdser stock were mixed,
evaporated, resuspended in 500 µl resuspension buffer, sonicated for 1 min at
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15% on ice. Eighteen microliters water, 2 µl cold ATP, 5 µl purified PI3K
(Echelon), 50 µl PIP2/Ptdser, and 20 µl γ32P-ATP were mixed and incubated at
room temperature overnight. The reaction was stopped by adding 100 µl of 1M
HCl and 10 µl Ptdser.Ptdser was preparing the carrier lipid at a concentration of
5 mg/ml,drying out 40 µl , then resuspending in 400 µl resuspension buffer and
sonicating)+ chloroform:methanol (1:2) + 0.5N NaCl in 0.1 N HCl. The obtained
ratio was: 0.1:0.3:0.1.
The reaction was vortexed and centrifuged for 5 min at 10,000 x g. The bottom
layer was dried and resuspended in 500 µl of lipid resuspension buffer. 145 µl
of obtained solution was added to cell lysates or 55 µl was added to purified
proteins reaction. In each case, 30 µl of substrate was utilized. This was
followed by 2-h incubation at 37°C.
For cell lysate reaction,1M HCl, Ptdser, Chloroform:Methanol, 0.5N NaCl in 0.1
HCl were added as: 85 µl,40 µl, 900 µl, 300 µl.For purified protein reaction, 55
µl,10 µl, 450 µl, 150 µl of each reagent was used. Bottom phase was used for
TLC.

PI3K Assay
2 mg/ml of cold PIP2 and 5 mg/ml of Ptdser were each dissolved in
chloroform:methanol: 10 mM HCl (20:9:1). 20 µl of Ptdser mixed with 50 µl PIP2
were mixed, evaporated, and resuspended in 300 µl of resuspension buffer
then sonicated for 1 minute at 15% on ice. 200 µl of kinase buffer was added,
along with 32 µl cold 2.5 mM ATP (to a final concentration of 160 µM) and 1 µl
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γ32P ATP. 100 µl substrate was mixed with 100 µl of cell lysate and incubated
for 2 hours at 37°C. Reaction was stopped by adding 5 µl Ptdser (made by
preparing the carrier lipid at a concentration of 5 mg/ml,drying out 40 µl , then
resuspending in 1000 µl

resuspension buffer and sonicating). For each

reaction,1M HCl, chloroform:methanol, 0.5N NaCl in 0.1 HCl were added as:
100 µl, 900 µl, 300 µl. Reaction was centrifuged for 3 minutes. Bottom phase
was used for TLC analysis.

Microscopy
HEK293T cells (Ci and G2i) stable expressing GFP-FGFR2 were transfected
with an empty mCherry vector or Akt-PH-mcherry using metafectene fllowing
manufacturer’s instructions. Success of transfection was detected via western
blot analysis. Serum starved cells on glass coverslips were fixed with 4%
(wt/vol) paraformaldehyde, pH 8.0 for 20 minutes when transfected with the
domains. Cells were then washed with PBS, to be mounted onto a slide with
mounting buffer (0.1% p-phenylenediamine/75% glycerol in PBS). Imaging was
performed using a confocal microscope (model SP5; Leica) to detect
colocalization between mcherry tagged construct and GFP used as a
membrane marker to indicate membrane localization of the domain.

RPPA Analysis and Heat Map Generation
Cell lysates (Ci and G2i cells in triplicates) were submitted to the RPPA core
facility. Based on the technical information provided by the facility, “the samples
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were two-fold-serial diluted for 5 dilutions and arrayed on nitrocellulose-coated
slide in 11x11 format. Samples were probed with antibodies by CSA
amplification approach and visualized by DAB colorimetric reaction. Slides were
then scanned on a flatbed scanner to produce 16-bit tiff image. Spots from tiff
images were identified and the density was quantified by MicroVigene. Relative
protein levels for each sample were determined by interpolation of each dilution
curves from the "standard curve" (supercurve) of the slide (antibody).
Supercurve is constructed by a script in R written by Bioinformatics. These
values (given as Log2 values) are defined as Supercurve Log2 (Raw) value". All
the data points were normalized for protein loading and transformed to linear
value designated as "Linear after normalization". The linear values were used
for "bar graph" generation were the error bars indicate the calculated standard
deviation. Heatmaps for an Unsupervised Hierarchical cluster (unsupervised on
both antibodies and samples (data not shown)) and an antibody unsupervised
but samples in order were provided. The heatmap included was generated in
Cluster 3.0 (http://www.eisenlab.org/eisen/) as a hierarchical cluster using
Pearson Correlation and a center metric. The resulting heatmap was visualized
in Treeview {http://www.eisenlab.org/eisen/) and presented as a high resolution
.bmp format.”

Cell fractionation
HEK293T cells (Ci and G2i) were serum starved overnight and then washed 3X
with PBS. Subcellular Protein Fractionation Kit for Cultured Cells (Thermo
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SCIENTIFIC) was used according to manufaturer’s instructions. Following
protein quantification, western blot analysis was performed where FGFR2 was
used as a membrane marker, and β-actin as cytoplasmic marker.

TCGA analysis
We downloaded and analyzed data publicly available from the Cancer Genome
Atlas Project (TCGA; http://tcga-data.nci.nih.gov/) for eleven tumor types:
bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), colon
adenocarcinoma (COAD), glioblastoma multiforme (GBM), head and neck
squamous cell carcinoma (HNSC), kidney clear cell carcinoma (KIRC), lung
adenocarcinona (LUAD), lung squamous cell carcinoma (LUSC), ovarian
serous cystadenocarcinoma (OV), thyroid carcinoma (THCA), uterine corpus
endometrial carcinoma (UCEC). Level 3 Illumina RNASeq (versions 1 and 2),
respectively RPPA data were used to extract mRNA and protein expression
levels. Analyses were performed in R (version 2.14.2) (http:///www.rproject.org/) and the statistical significance was defined as a p-value less 0.05.
The Spearman's rank-order correlation test was applied to measure the
strength of the association between mRNA and RPPA levels across tumor
types. A box-and-whisker plot was used to visualize RPPA levels across tumor
types.
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Molecular cloning
Empty mCherry vector was used in the experiments along with Akt-PH domain
cloned in mCherry vector. The kinase dead cytoplasmic portion of FGFR2
(residues 413-821) was generated through a point mutation (K517I) in the
catalytic region. Grb2 was also cloned in a myc tagged pCDNA3.1 mammalian
expression vector.

Protein expression and purification
6Xhistidine-tagged constructs of FGFR2, and Grb2 were expressed and purified
from E. coli as previously described (3).

Measurement of PIP3 level in whole cells
Measurement

of

steady-state

content

of

bisphosphate (PtdIns(3,4,5)P3) was performed in

phosphatidylinositol

3,4,5-

[3H]myo-inositol uniformly

radiolabelled cells. HEK293T cells were prelabeled with myo-[2-3H(N)]inositol
(1µCi/ml) (Perkin-Elmer) for 24 h in inositol and serum-free DMEM medium
and then washed with PBS. After labeling, the cells were harvested, washed,
and subjected to lipid extraction and TLC analysis.

Lipid extraction and TLC Analysis
The cell pellet was resuspended in 0.2 ml of 0.5 N NaCl in 0.1 N HCl and 0.6 ml
chloroform: methanol (1:2) was added and the suspension was vigorously
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vortexed for 30 min. 0.2 ml of 0.5 N NaCl in 0.1 N HCl was added followed by
vortexing for 10 min. After 5 min of centrifugation on Eppendorf Table
Centrifuge, upper water-methanol phase was discarded and lower chloroform
lipid phase was transferred to an Eppendorf tube.
Lipids extracts were used in thin layer chromatography (TLC) analysis. 25,000
cpm aliquots were brought to same volume with chloroform. The phospholipids
were analyzed by silica gel TLC after separation by one-dimensional TLC on
potassium oxalate impregnated silica gel plates using a solvent system
containing

chloroform/methanol/ammonium

hydroxide/water

(57:50:4:11,

v/v/v/v) to separate PtdIns(4,5)P2, PtdIns(3,5)P2 , and PtdIns(3,4,5)P3

from

one another.
20 cm high-performance Partisil LK5 silica gel precoated TLC plates with a
concentration-zone (Whatman Inc. Clifton, NJ) were impregnated for 1 min in
1.2 % (w/v) potassium oxalate in methanol-water (2:3). After air drying, the
plates were desiccated at 100°C for 60 min before use. Radiolabeled lipids
were visualized and quantified using a Personal Molecular ImagerTM FX (BioRad Laboratories). Stored images were processed and quantified using
Quantity One software for scanning and analysis of the captured Phosphor
images (Bio-Rad Laboratories). Phospholipid content is expressed as mol% of
total phospholipid based on the pixel intensity of the captured signal on
Phosphor screen generated by the radiolabeled spots on the TLC plate.
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Xenograft mouse model and magnetic resonance imaging (MRI)
Adult female nude mice were injected with 0.5 x106 PCi, PG2i, PPγi, Ci, G2i ,
and Pγi cells in PBS (4 mice per group). Injections were done subcutaneously
in the right flank of the animal. After 60 days and for MRI imaging, mice were
scanned on a 4.7T Biospec USR47/40 small animal imaging system (Bruker
Biospin MRI, Inc., Billerica, MA) with a 35-mm linear volume resonator and 60mm micro-imaging gradients. A three-plane FLASH imaging sequence was
used to confirm animal positioning, and coronal and axial T2-weighted RARE
images (TE/TR 57/3000ms, FOV 4cm × 3cm, matrix 256 × 192, RARE factor
12) were used for tumor localization and volume measurement.
For tumor volume calculation ROI was created in imageJ software that
surrounds tumors in the axial sections (for every slice). The areas of the ROIs is
in mm2. ROI areas were then summed up and multiplied by the slice thickness
(0.75 mm for all of the scans). This is the volume of tumor within the image
slices. To account for the slice gap between adjacent slices (0.25 mm for all of
the scans), the mean of the ROI areas for each pair of adjacent slices was
computed then the sum of these means is multiplied by 0.25 mm to get an
estimate of the tumor volume between slices. The tumor volume estimates were
then added within slices and between slices to get the total tumor volume in
mm3. Tumor volumes for mice in each group were averaged.
Following imaging, mice were sacrificed, tumors were weighed and weights
were averaged in each group and plotted as bar graph where the standard
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deviation of the mean is denoted by error bars. Half of each tumor was used for
western blot analysis and the other half for immunohistochemistry (IHC).
Proteins used in western blot analysis were extracted via sonication up to 30
minutes on ice at low setting (to efficiently separate the lipid fraction found on
top of protein layer). This was followed by centrifugation at 13000 rpm for 15
minutes at 4°C. The supernatant containing the proteins was transfered to a
new tube. IHC was performed on paraffin embedded tumors sectioned at 5 µm.
Hematoxylin and eosin staining along with pAkt (serine 473) antibody staining
were performed on rehydrated samples followed by visualization. This was
done using automated Leica Bond III- autostainer (Department of Veterinary
Medicine & Surgery at MD Anderson Cancer Center). For that, slides were
baked at 60⁰C for 30 minutes then the temperature was increased to 72⁰C.
Slides were then rinsed 3 times with Bond Dewax followed by absolute alcohol
and Bond Wash. Temperature was then increased to 100⁰C, and Bond ER
Solution 1 (ph6) was applied and incubated for 30 minutes. Slides were rinsed
with Bond Wash and temperature was allowed to come down to room
temperature.

Antibody Phospho-Akt (Ser473) (D9E) XP Rabbit mAb #4060

(Cell Signaling Technology) was applied at 1:50 dilution and incubated for 15
minutes at room temperature followed by rinsing with Bond Wash. Post Primary
was applied and incubated for 8 minutes then slides were again rinsed with
Bond Wash. Bond Polymer was applied and incubated for 8 minutes followed
by rinsing with Bond Wash 2 times then DIH₂O. Peroxide Block was applied and
incubated for 5 minutes then rinsed with Bond Wash 4 times then with DIH₂O.
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DAB was applied and incubated for 10 minutes then rinsed with DIH₂O 3 times.
Hematoxylin was applied and incubated for 7 minutes then rinsed with Bond
Wash. Slides were then removed from Leica Bond III and rinsed with DIH₂O 4
times. They were then dehydrated in graded alcohols and xylene then
coverslipped with ClearMount from American MasterTech using Leica CV5030
coverslipper.
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Results
Grb2 depletion increases cell proliferation
In non-stimulated FGFR2-over-expressing HEK293T G2i cells, the number and
size of anchorage-independent colonies was dramatically increased compared
with Ci cells (Figure 4.2a,b,c,d). Furthermore, colony formation was abrogated
in parental HEK293T cells, which express low levels of endogenous FGFR2
(Figure 4.2a,e). Therefore, colony formation was associated with constitutive
Grb2-FGFR2 complex formation (2), which inhibits protein recruitment to the
receptor C-terminus (59). Anchorage-independent growth was independent of
the MAPK pathway as evidenced by the lack of effect of the potent MAPK
inhibitor U0126 on colony formation (Figure 4.2b,c and Fig4.3a,b).
Because Grb2 is a key component of the RTK-mediated up-regulation of the
MAPK pathway, which is linked to proliferative response, increased colony
growth in the absence of Grb2 was a surprising observation. The absence of a
MAPK proliferative signal strongly implicated PI3K/Akt pathway activation in the
observed colony formation.
FGFR2-mediated anchorage-independent growth was dependent on Plcγ1
because colony formation was largely abrogated in G2i cells treated with the
phospholipase

inhibitor

U73122

(Figure

4.2b,c).

Furthermore,

Plcγ1

knockdown in GFP-FGFR2-over-expressing HEK293T (Pγi) cells and parental
cells stably transfected with empty GFP vector (PPγi) inhibited colony formation
(Fig4.3c-f). Thus, anchorage-independent growth was specifically dependent
on high FGFR2, low Grb2, and high Plcγ1 expression levels.
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Fig 4.2: FGFR2 is required for Akt-dependent colony formation in Grb2
knockdown cells.a) Parental and FGFR2-overexpressing HEK293T cells were
transfected with scrambled and Grb2 shRNAs to generate PCi and PG2i and Ci
and G2i cell lines, respectively. Western blot analysis was done to determine
the efficiency of FGFR2 transfection and Grb2 knockdown. Arbitrary numbers
on the blot represent densitometric analysis performed via Image J software.b)
Soft agar assay was used to determine anchorage-independent growth in Ci
and G2i cells. The lower layer consisted of DMEM/agar containing 1% FBS.
The upper layer consisted of a single cell suspension (0.6 x104)in serum-free
DMEM/agar.Colony formation was determined after 8 d. DMEM containing 1%
FBS with or without the indicated inhibitors was added to the wells once a
week. c) The number of colonies was counted in different microscopic fields
and normalized to Ci cells in serum-free DMEM. Values shown represent the
mean ± standard deviation of three independent experiments. d) Magnification
of colony formation in GFP-FGFR2-overexpressing Ci andG2i cells.e)
Anchorage-independent growth was determined in parental HEK293Tcells
using soft agar assay as described in b.
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Fig 4.3: Plcγ1 is required for FGFR2 to induce Akt-dependent colony
formation. a) Soft agar assay was used to evaluate anchorage-independent
growth in Ci and G2i cells. The lower layer consisted of DMEM/agar containing
1% FBS. The upper layer consisted of a single cell suspension (0.6 x104) in
serum-free DMEM/agar. After 8 days, DMEM containing 1% FBS with or
without the indicated inhibitors was added to the wells once a week. Pictures of
the entire well were taken.b)The number of colonies was counted and
normalized to Ci cells in serum-free DMEM. Values shown represent the mean
± standard deviation of three independent experiments.c) Parental and FGFR2overexpressing HEK293T cells were transfected with scrambled, Grb2 and
Plcγ1 shRNAs to generate PCi, PG2i, and PPγi and Ci, G2i, and Pγi cell lines,
respectively. The efficiency of Grb2 andPlcγ1 knockdown and FGFR2
transfection was confirmed by western blot analysis.d) Soft agar assay was
done to evaluate anchorage-independent growth in Ci, G2i, Pγi, PCi, PG2i, and
PPγi cells as described in a.e) The number of colonies wascounted and
normalized to PCi cells in DMEM containing 1% serum. Values shown
represent the mean ± standard deviation of three independent experiments.f)
Magnification (5x) of colony formation in one microscopic field for Ci, G2i, Pγi,
PCi, PG2i, and PPγi cells.
PI3K activity is unaffected in Grb2-depleted cells
We previously reported that Grb2 depletion in non-stimulated cells up-regulated
Plcγ1, leading to turnover of plasma membrane PIP2 (59). In addition to Plcγ1,
cellular PIP2 concentration of is regulated by PI3K and PTEN. Therefore, we
determined whether PI3K and PTEN were involved in the proliferative cellular
response in non-stimulated G2i cells.To do this, reverse phase protein array
(RPPA) was used to assess the expression and/or phosphorylation of select
proteins and effectors of the PI3K and PTEN pathways in non-stimulated Ci and
G2i cells (Fig 4.4a). A comprehensive heat map is shown in Fig 4.5 andTable
4.1. The expression level of the p85 and p110 subunits of PI3K were not
appreciably changed between G2i and Ci cell lines (Fig 4.4b). The addition of
the PI3K inhibitor wortmannin reduced colony formation in Ci and G2i cells,
suggesting the presence of constitutive PI3K activity in both cell lines (Fig 4.2
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b,c). PI3K converts PIP2to PIP3; therefore, the constitutive PI3K activity in G2i
cells suggested that the combined activities of Plcγ1 and PI3K deplete the pool
of PIP2to reduce the PIP2/PIP3 ratio (see schematic in Fig 4.1).

a
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Fig 4.4 Increased phosphorylation of Akt in G2i cells is independent of
PI3K and PTEN expression. a) Heat map of the log2 values of triplicate
samples from Ci and G2i cells. The heat map was generated from the original
heat map provided by the facility using theR console statistical package.b-i)
Linear values normalized to control cells were used to construct bar graphs of
the ratios of phosphorylated protein to total protein, phosphorylated protein to
actin, and total protein to actin.
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Fig 4.5 Phosphorylation levels of Akt and its downstream effectors is
higher in G2i cells compared with Ci cells. RPPA heat map showing the
phosphorylation levels of Akt and its downstream effectors in G2i and Ci cells.
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Table 4.1 Linearized values obtained from the RPPA analysis of G2i and Ci
cells. Linearized values of the expression and/or phosphorylation of PTEN and
Akt and their downstream effectorsfrom the RPPA analysis of G2i and Ci
cellsare shown. Linear values were averaged, normalized tocontrol cells, and
used to generate bar graphs.

In Ci cells, the pool of PIP2 is not as severely affected because Plcγ1 is inhibited
in the presence of Grb2. Addition of the PI3K-specific inhibitor wortmannin
reduced PIP3 production in Ci cells; therefore, PI3K contributed in part to PIP2
depletion (Fig 4.6a,b). Intracellular level of PIP3 in myo-[2-3H(N)]inositol-labeled
Ci and G2i cells was also measured in Fig 4.6c and it appeared to increase
upon knocking down Grb2.
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Fig 4.6 PIP3 to PIP2 ratio is higher in G2i cells compared with Ci cells and
is independent of PI3K p85 phosphorylation level and activity. a) PI3K
kinase assay was performed on cell lysates obtained from untreated
andwortmannin-treated Ci and G2i cells. Cell lysates were incubated32P-labeled
ATP and unlabeled PIP2, PI3K substrate. PIP3 product and remaining PIP2
substrate were separated by TLC. b) PI3K kinase assay data was volume
adjusted (pixel percentage and normalized to untreated control cells were
obtained in duplicates visualized and quantified for adjusted volume. c) Lipid
was extracted from cell lysates obtained from myo-[2-3H(N)]inositol-labeled Ci
and G2i cells . PIP3 was identified by TLC based on the Rf value and quantified
at the pixel level.
PTEN activity is down-regulated in Grb2-depleted cells
The effect of PI3K on PIP3 production is reversed by PTEN phosphatase
activity, which restores membrane PIP2 concentrations. Incubation of G2i cell
lysates with

32

P-PIP3 inhibited the ability of PTEN to restore PI(4,5)P2 levels,

resulting in a dramatic reductioninPIP2/PIP3ratio (Fig 4.7a). RPPA analysis
showed that PTEN expression was not significantly different between G2i and
Ci cells (Fig 4.4c). Because PTEN binding to PIP2 is required to induce its
activity, the reduction in the PIP2 pool resulting from combined Plcγ1 and PI3K
activitiesin G2i cells may affect the ability of PTEN to turnover PIP3. In other
words, PIP2 depletion negatively regulates PTEN, resulting in the accumulation
of PIP3.To demonstrate that the increase in PIP3 in G2i cells is dependent on
PTEN, cells were treated with the PTEN inhibitor SF1670. PTEN inhibition
using SF1670 reduced PIP2/PIP3 ratio (Fig4.7a). Furthermore, inhibition of
Plcγ1 using U73122 reduced PIP2 concentration and PIP2/PIP3 in G2i cells to
that of Ci cells (Fig 4.7a). To determine whether Plcγ1 affects PTEN
phosphatase, Ci cells were either left untransfected or transfected with wild-type
Plcγ1. PTEN activity was lower in Plcγ1-transfected Ci cells than in
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untransfected Ci cells (Fig 4.7b). Together, these findings indicated that Plcγ1mediated PIP2 depletion disables PTEN activity.
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Fig 4.7 Plcγ1-mediated PIP2 depletion negatively regulates PTEN activity
in G2i cells.a) Cell lysates were obtained from cells treated with the Plcγ1
inhibitor U73122 or the PTEN inhibitor. Cell lysates from untreated cells served
as a control. Cell lysates were incubated with 32P-labeled PIP3, and TLC was
used to separate and identify PIP2 and PIP3 (top panel). PIP2/PIP3ratioswere
generated from the pixel data and are presented as the mean ± standard
deviation of three independent experiments (bottompanel). *p ≤ 0.05 and **p≤
0.01 (Student’s t-test).(b) Ci cells were left untransfected or transfected with
Plcγ1.Cell lysates were incubated with 32P-labeled PIP3, followed by TLC
analysis and PIP3/PIP2 ratio quantification as described in a. c,d) Various
combinations of purified proteins including Plcγ1, Grb2, PTEN, and kinase dead
(KD) FGFR2wereincubated with 32P-labeled PIP3, followed by TLC analysis and
PIP3/PIP2 ratio quantification as described in a. Values shown represent the
mean ± standard deviation of triplicatesamples. e,f) Purified PTEN was
incubated with Ptdser and [32P]-PI (3,4,5)P3 in the presence or absence of 33
µg/µl cold PIP2. 32P-PIP2 and PIP3 were separated by TLC, visualized, and
quantified at the pixel level (top panel). PIP2/PIP3 ratios were generated from
the pixel data and are presented as the mean ± standard deviation of two
independent experiments (bottom panel).

Inhibition of PTEN using SF1670 slightly increased colony formation in G2i cells
(Fig 4.2b,c and Fig 4.3a,b). As expected, the effect of PTEN inhibition on
colony formation was more dramatic in Ci cells. This is because the
suppressive activity of PTEN is abrogated in Ci cells. Our finding corroborates
the fact that, in normal cells, constitutive PTEN activation restores plasma
membrane PIP2.
To further examine the relationship between Plcγ1 and PTEN in vivo, we
utilized purified proteins in an in vitro reconstitution assay. KD FGFR2 and
Plcγ1 were added to PTEN in the presence and absence of Grb2. PIP3
accumulation was more dramatic in the absence of Grb2 compared with the
presence of Grb2 (Fig4.7c, d) Thus, the increased turnover of PIP2 by Plcγ1 in

	
  

135	
  

the absence of Grb2 decreases PTEN activity and results in the accumulation
of PIP3.
To confirm that PI(4,5)P2 is needed for the stabilization of PTEN activity, purified
PTEN was incubated with

32

P-PIP3 and Ptdser in the absence and presence of

cold PIP2.The activity of PTEN was dramatically enhanced in the presence of
PIP2 (Fig4.7e,f).

Akt is upregulated in Grb2-depleted cells
The inactivity of PTEN in G2i cells results in the accumulation of PIP3, on which
Akt binds. Upon binding to the membrane, Akt is phosphorylated and
downstream signaling ensues. Accumulation of PIP3 with respect to PIP2 in the
absence of Grb2 is reflected in the increased expression of phosphorylated Akt
(pAkt) (Fig 4.3a,d) and its downstream effectors including mtor glycogen
synthase kinase 3 (Gsk3; Ser21; Fig 4.3f), p70 S6 kinase (p70S6K; Thr389,
Ser235, and Ser240; Fig 4.3g), S6 ribosomal protein (Ser235/236 and
Ser240/244; Fig 4.3h), and proline-rich Akt substrate 40 (Pras; Thr246; Fig
4.3i) in G2i cells compared with Ci cells. Thus, Plcγ1 activation in the absence
of Grb2 indirectly increased Akt activation and downstream signaling in nonstimulated HEK293T cells.
Elevated levels of pAkt (S473 and T308) were observed in G2i cells compared
with Ci cells (Fig 4.8a). Treatment of G2i cells with the PTEN inhibitor SF1670
increased Akt phosphorylation.Furthermore, Akt phosphorylation was inhibited
by the forced expression of Grb2 in G2i cells (Fig 4.8b).
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findings demonstrated that Akt phosphorylation was dependent on PTEN.
Interestingly, PTEN phosphorylation was increased in G2i cells compared with
Ci cells, whereas Grb2 overexpression decreased PTEN phosphorylation in G2i
cells (Fig 4.8b).
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Fig 4.8 PTEN-mediated Akt phosphorylation and activity is dependent on
Grb2 and Plcγ1 concentrations. a)Western blot analysis was done to
determine the expression of pAkt (Ser473 and T308) in cell lysates obtained
from untreated and SF1670-treated Ci and G2i cells.b) Western blot analysis
was done to determine the expression of pAkt (Ser473) and phosphorylated
PTEN (S380/T382/383) in cell lysates obtained from Ci, G2i, and Grb2 knock in
G2i cells.c) Western blot analysis was done to determine the expression of total
Plcγ1, Grb2, and pAkt (Ser473) in Ci, G2i, and Pγi cells.d) Western blot
analysis was done to determine the expression of pAkt (Ser473 and T308) in
cell lysates obtained fromuntreated and U73122-treated Ci and G2i cells.e)
Western blot analysis was done to determine the expression of phosphorylated
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PDK1 (Ser241) in cell lysates obtained from Ci and G2i cells.f) Ci and G2i cells
were left untreated or treated with the indicated inhibitors. Akt kinase assay was
performed on the cell lysates. Western blot analysis was used to detect the
effect of the inhibitors on kinase activity.g) Akt kinase assay was performed on
Ci, G2i, and Pγi cell lysates. In all western blot analyses, β-actin was used as a
loading control.
Phosphorylation of PTEN inhibits its phosphatase activity, thereby facilitating
PIP3 accumulation and Akt recruitment. Inhibition of Akt using Akt inhibitor VIII
reversed the Grb2-dependent Akt phosphorylation (Fig 4.9a) and inhibited
colony formation (Fig 4.2b,c and Fig 4.3a,b).In addition, we demonstrated that
Akt phosphorylation in G2i cells was linked to PI3K activity because, in the
presence of wortmannin, pAkt was decreased (Fig 4.9b) even though PI3K
activity wassimilar between Ci and G2i cells. Conversely, Akt phosphorylation
was independent of MAPK pathway activation as demonstrated by the
negligible effect of the MEK inhibitor U0126 on pAkt levels (Fig 4.9c).
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Fig 4.9 Akt phosphorylation is PI3K dependent and MAPK independent in
Ci and G2i cells. a) Western blot analysis was done to determine the
expression of pAkt (Ser473) in cell lysates obtained from untreated andAkt
inhibitor VIII-treatedCi and G2i cells. b) Western blot analysis was done to
determine the expression of pAkt (Ser473 and T308) in cell lysates obtained
from untreated and wortmannin-treated Ci and G2i cells.c) Western blot
analysis was done to determine the expression of phosphorylated Erk1/2 and
pAkt (S473) in untreated and U0126 (MEK1/2 inhibitor)-treated Ci and G2i
cells.β-actin was used as a loading control in all western blot analyses.

To demonstrate that Akt phosphorylation was dependent on Plcγ1, Plcγ1 was
inhibited using Plcγ1 knockdown (Pγi) cells and U73122. Akt phosphorylation
was decreased in Pyi cells (Fig 4.8c) and U73122-treated cells (Fig 4.8d).
These data further support that the reduction in PIP2 concentration as a result of
Plcγ1 activity inactivates PTEN, resulting in Akt activation.
Since PDK1 protein which phosphorylates Akt on T308 also binds to PIP3
resulting in phosphorylation and activation, we decided to study its
phosphorylation status in Ci and G2i cells (Fig 4.8e). As expected, its
phosphorylation level is higher in G2i cells compared to Ci cells.
To confirm that the increase in Akt phosphorylation level is accompanied by an
increase in its activity, we immobilized total Akt from Ci and G2i cells on A/G
agarose beads and incubated them with purified GSK (Akt substrate) in the
presence of ATP. This kinase assay (Fig 4.8f, 4.8g) showed an increase in Akt
activity in G2i cells compare to Ci and Pγi cells. U73122, and Wortmannin
decreased the activity of Akt but U0126 had little or no effect unlike SF1670,
which enhanced the activity. These results match the ones obtained for the
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phosphorylation status of this kinase. Thus, Plcγ1 dependent decrease in PTEN
activity in G2i cells is reflected in a decrease in the activity of Akt.
To confirm that the constitutive activation of Akt is dependent on the recruitment
of the kinase to the plasma membrane in G2i cells we used HEK293T cells
over-expressing N-terminally GFP-tagged FGFR2. Since in non-stimulated cells
FGFR2 is membrane localized this provides a clear marker for the cell
membrane.
We also expressed the PH domain of Akt (Akt-PH) with a mCherry fluorescent
fusion protein tag (an empty mCherry vector was used as a control; Fig 4.10a).
The PH domain has previously been reported to be responsible for the
recruitment of Akt to the membrane on stimulation. In Ci cells there is no colocalization of the fluorescent tags reflecting the lack of recruitment of Akt-PH to
the membrane (Fig 4.10b), however in the G2i cells clear co-localization of AktPH to the membrane is observed. This is consistent with the observation that
Akt translocates to the PIP3-rich plasma membrane to be phosphorylated in G2i
cells.
We confirmed these results by performing a fractionation experiment in Ci and
G2i cells where actin was used as a cytoplasmic marker and FGFR2 as a
membrane marker (Fig 4.10c). A larger population of Akt was found in the
membrane in G2i cells compared to Ci cells. This is consistent with the
increased pool of PIP3 observed in G2i cells serving to recruit Akt.
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Fig 4.10 Membrane localization of lipid binding Akt-PH domain is higher in
G2i cells compared to Ci cells.a) Ci and G2i cells transfected with an empty
mCherry vector or mCherry-Akt-PH vector were serum starved, lysed and used
for western blot analysis where the blots were probed with the indicated
antibodies.b) Ci and G2i cells transfected with an empty mCherry vector or
mCherry-Akt-PH vector were serum starved and used for microscopy as
explained in the Materials and Methods section. FGFR2-GFP was used as a
membrane marker to show co-localization of the lipid binding PH domain on the
membrane bound FGFR2.c) Serum starved Ci and G2i cells were fractionated
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into membrane and cytoplasmic portions, lysed and used for western blot
analysis then probed with the indicated antibodies.
Akt phosphorylation is concomitant with reduced Grb2 and increased
Plcγ1 concentrations in uterine corpus epithelial cancer (UCEC)
According to our data depletion of Grb2, concomitant up-regulation of Plcγ1 and
subsequent phosphorylation of Akt should be manifest in cancer. We would
expect that cells expressing FGFR2 accompanied by low Grb2 and high Plcγ1
concentrations would exhibit higher oncogenic prevalence. To confirm the
physiological relevance of our observations we performed a comprehensive
analysis using “The Cancer Genome Atlas” database.
RPPA data on PI3K/PTEN/Akt expression and/or phosphorylation levels in
different types of patient tumor samples were extracted. Inverse correlation
between the Grb2 concentration and phosphorylation of Akt (on both S473 and
T308) were observed in several tumor-types (Fig 4.11a (S473), 4.11b (T308)).
Furthermore, pAkt was also seen in several tumor-types with high Plcγ1
expression (Fig 4.11c (S473), 4.11d (T308)). Uterine corpus endometrial
carcinoma (UCEC) which is one of the most common cancers of the female
reproductive system showed a particularly strong correlation between pAkt with
low Grb2 and high Plcγ1 concentrations.
This is consistent with our observations in the HEK293T model cell line reported
herein. The RPPA results for tumor types for both S473 and T308 are shown in
Fig 4.11e, 4.11f.
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Fig 4.11 Akt phosphorylation level is among the highest in UCEC and it
negatively correlates with Grb2 expression but positively correlates with
Plcγ1 expression. a),b),c),d) Data was downloaded from TCGA website for
eleven tumor types as described in the materials and methods section. Level 3
Illumina RNASeq versions 1 and 2 RPPA data were used for mRNA and
protein expression level. Statistical analysis was performed in R (version
2.14.2) where p-value > 0.05 is considered to be significant and is shown in red.
p-value< 0.05 is shown in blue. The Spearman's rank-order correlation test was
performed to measure the strength of the association between Grb2 mRNA and
pS473/pT308 RPPA levels in a) and b) respectively and also between Plcγ1
and pS473/pT308 RPPA levels in c) and d) respectively across different tumor
types. e),f) A box-and-whisker plot was used to visualize RPPA levels across
tumor types following TCGA database analysis.

Grb2 depletion results in enhanced tumor formation in xenograft mouse
model with increased Akt phosphorylation level
PCi, PG2i, PPγi, Ci, G2i, and Pγi cells were used in the generation of a
xenograft mouse model where 0.5 x 106 cells were subcutaneously injected in
the right flank of adult female nude mice (4 mice per group). After 60 days, mice
were subjected to MRI scanning as explained in the method section to
determine tumor volume in every case. As can be seen in the first panel in Fig
4.12a , which corresponds to the coronal section, mice injected with G2i cells
showed drastic increase in tumor size and also the development of multiple
tumors in the vicinity of the primary one compared to mice injected with Ci and
PG2i cells. PCi injection failed to develop noticeable tumors as in the case of
Pγi and PPγi (results not shown).
These results are clear in the second panel and also in the third panel which
corresponds to the axial sections. Tumor weight and volume (Fig 4.12b) are
also higher in G2i tumors compared to Ci and PG2i tumors. This outcome is
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consistent with the one obtained in colony formation assay where G2i cells
were relatively unique in their ability to form multiple colonies of increased size.
Ci and G2i tumors were used in western blot analysis as shown in Fig 4.13a.
As expected, G2i tumors expressed a higher level of Akt phosphorylation
compared to Ci tumors. Total Akt and actin were used as loading controls in
both cases.
Morphologically, the G2i tumor cells have a higher grade of malignancy than Ci
tumor cells (Fig 4.13b). Ci tumor appears to be composed of densely cellular
and poorly differentiated neoplastic cells that have small/minimal amount of
eosinophilic cytoplasm and oval or pleomorphic nuclei. The nuclei have
hyperchromatic, coarse or stippled chromatin and prominent one or two
nucleoli. The tumor has delineated margins and is surrounded partially by a
fibrous capsule. There is a high mitotic rate of approximately 60-70 mitotic
figures per 400x magnification field. Numerous apoptotic cells are present. The
tumor has a few small areas of necrosis representing approximately 5-10% of
the entire tumor. G2i tumor is composed of similar type of neoplastic cells, but
more anaplastic or higher degree of cellular pleomorphism. These neoplastic
cells have lower amount of cytoplasm. The nuclei are markedly pleomorphic
and have severely coarse, stippled or clumped hyperchromatic chromatin, and
prominent multiple nucleoli. A similar high number of nuclear mitotic figure are
present. There is increased number of apoptotic cells and large areas of
necrosis affecting approximately 60-70% of the entire tumor. The margins of the
tumor are indistinct and there is infiltration of tumor cells into the fibroadipose
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tissue at the periphery of tumor. As shown in Fig 4.13c Ci tumor cells stained
negative for pAkt (serine 473) antibody. There is only a minimal nonspecific
background staining. Also, the necrotic areas of tumor have nonspecific/false
staining. In the G2i sample, there is positive staining of these tumor cells. The
staining is more intense in the tumor cells from the perivascular regions.
Nonspecific/false background staining of the necrotic areas is also present.
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Fig 4.12 Tumor formation is drastically enhanced in mice injected with
Grb2 knockdown cells in a background of FGFR2 expression a) First panel:
Coronal MRI images of PCi, PG2i, Ci, G2i injected mice following 60 days of
subcutaneous injections. Arrows indicate the tumors formed. Second panel:
Sample from each group showing absence of tumor (PCi injected mice) or
size/number of tumors formed in every group. Third panel. Axial MRI images of
PCi,PG2i,Ci,G2i injected mice following subcutaneous injections. Arrows
indicate the tumors formed. b) Tumors from every group were weighed and
averaged. Bar graphs were plotted and error bars denote standard deviation of
the mean. Tumor volumes were calculated for mice in every group as explained
in details in the methods section.
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Fig 4.13 G2i cells form tumors of a higher grade of malignancy compared
to Ci tumors and have a higher level of Akt phosphorylation a) Tumor
sections were sonicated and proteins were extracted and used for western blot
analysis where the blots were probed with the indicated antibodies. b) H & E
staining of Ci and G2i tumors taken at 40x and 600x. c) pAkt staining of Ci and
G2i tumors taken at 40x, 200x,and 400x.
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In summary, competition between Plcγ1 and Grb2 for binding to FGFR2
controls membrane levels of PIP2 which in turn affects the phosphatase activity
of PTEN.Consequenly the phosphorylation statuts and activity of Akt can be
modulated accordingly where high levels of Akt phosphorylaion is evident in G2i
tumors (tumors formed in xenograft models following the injection of Grb2
knockdown cells in mice).
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Chapter Five: Discussion
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SH3 domains of Grb2 and Plcγ1 compete for the same binding site on
FGFR2
The novel results presented in Chapter 2 represent a critical principle in
FGFR2-dependent cancer signaling, specifically that signal transductionmediated oncogenic outcome can be based entirely on the competition of nonphosphorylated ligands (namely Grb2 and Plcγ1) for a non-phosphorylated
protein binding site.
The measured KDs for the SH3 domains of both Grb2 and Plcγ1 binding to
FGFR2 is similar which means that the receptor binding site could be occupied
equally by either Grb2 or Plcγ1 under equimolar conditions.
In normal cells the Grb2 concentration is assumed to be greater than that of
Plcγ1 since it is a critical adaptor protein required for the activation of several
pathways and thus under non-stimulated conditions Grb2-FGFR2 complex will
prevail.
This complex formation leads to the inhibition of the lipase activity of Plcγ1.
Nevertheless, any fluctuation in protein concentrations like a decrease in Grb2
(G2i cells) or increase in Plcγ1 and/or FGFR2 will allow the phospholipase to
out-compete the inhibitor causing an induction of constitutive and uncontrolled
phospholipase activity.
Since tyrosine kinase-mediated signal transduction is typically constrained by
stimuli mediated receptor activation/deactivation, the concentration-dependent
activation of the lipase seems to be under much looser regulation. The
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implications for disease can thus be mediated by protein concentration
fluctuations (Fig 2.1).
The described process of the SH3 domain-mediated activation of Plcγ1 can be
considered an additional mechanism to that which occurs upon the binding of
the lipase on pY769 following extracellular stimulation
The dynamics of such SH3 domain mediated basal state binding to the Cterminus of FGFR2 can possibly be dependent on a conformational change in
the structure of the lipase mimicking the previously well-established activation
caused by NSH2 domain binding. Plcγ1SH3 domain forms an interface with the
CSH2-SH3 linker region (residues 759-791) possibly playing a significant role in
stabilizing the auto-inhibited state (31). This interaction can in part occlude the
canonical proline-rich motif-binding site on Plcγ1SH3 thus basal state binding to
FGFR2 will destabilize the auto-inhibitory potential of the CSH2 domain by
disrupting the intramolecular SH3 interaction.
Also, it has been previously reported that isolation of the lipase SH3 domain
has negligible effect on the enzymatic activity (16), however deletion of the
domain does not replicate the effect of binding to FGFR2 and the consequent
conformational change. Interestingly, the CSH2 domain has been shown to
have some affinity to the CSH2-SH3 linker region in a phosphorylation
independent manner (31). Thus, the possible conformational perturbation
accompanying the Plcγ1SH3-FGFR2 interaction would expose the CSH2-SH3
linker region and the interaction of CSH2 with the linker will serve to reverse the
auto-inhibition. This is plausible especially after taking into consideration a
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similar mechanism where the split PH domain of Plcγ2 is critical and sufficient
for the activation of the lipase (60-64).

Grb2 and Plcγ1 competition controls lipase mediated cell migration and
invasion
Grb2 binds and interacts with several proteins thus depleting it would have
significant effects that could affect Plcγ1 activity and/or phospholipid turnover.
In this case cellular migratory and invasive potential could be influenced by the
fluctuation of protein concentrations via a mechanism independent of the one
described here. However, there are many critical points that should be taken
into consideration before making such an assumption. So far, this project has
provided evidence that the adaptor protein directly affects Plcγ1 lipase activity
by the following:
1) Grb2 and Plcγ1 compete for a binding site on FGFR2. When this receptor is
absent, like in HEK 293T parental cell line which express negligible levels of
FGFR2, the constitutive phospholipase activity is absent.
2) Depletion (via knockdown) or inhibition (via U0122) of Plcγ1 eliminates the
cellular effects observed, while knocking in the lipase rescues the phenotype.
3) Plcγ1 activity in other signaling pathways is evident only under conditions of
stimulation dependent receptor up-regulation. Here, FGFR2 was left unstimulated, and therefore was incapable of phosphorylating the lipase.
4) Both Grb2 and Plcγ1 bind to the protein Sos which initiates and activates the
downstream MAPK pathway (65). Knocking down Grb2 could result in the
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observed phenotype by increasing the influence of the lipase on MAPK
signaling. This hypothesis is unlikely since MAPK response is absent on Grb2
knock down (2).
5) Plcγ1 can get activated by non tyrosine kinases (NTKs). When Grb2 is
depleted (via knockdown), NTKs like Src Family kinases (SFKs) could become
up regulated and hence activate the lipase. In this case, the cells are under
basal conditions and NTKs are up regulated solely on stimulation by activated
receptors thus activity toward the lipase is improbable.
6) Grb2 mediates the downstream phosphorylation of PIP2 to PIP3 via PI3K. So,
in the absence of the former there can be an increase in the relative
concentration of PIP2. But since there is an obvious depletion of PIP2 in G2i
cells and a simultaneous increase in intracellular calcium levels, downregulation of PI3K activity cannot justify the observed phenotype.
It is also critical to analyze the reasons behind the evolution of the Plcγ1SH3
domain mediated constitutive interaction and activation of the lipase alongside
the previously well-established SH2 binding to activated FGFR2. The SH3dependent activation mechanism is highly plausible since it is based on the
concentration of the lipase where control of the intracellular level is a
“housekeeping” activity critical for the maintenance of membrane constitution
homeostasis and the subsequent intracellular calcium mobilization.
For example, there is growing evidence from a number of tissues like vascular
smooth muscle, that tyrosine phosphorylation is crucial yet inadequate to fully
activate the lipase. It might instead be critical for the translocation of Plcγ1 from
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the cytosol to the actin cytoskeleton (66). Also, it has been shown that in
Xenopus oocytes the binding of the SH3 domain to Sos induces pY783independent background phospholipase activity (67).
It is important to note that controlling intracellular signaling via the law of mass
action makes the cells more sensitive to fluctuations in protein concentrations.
As Plcγ1 expression level increases, it can contribute to oncogenesis and
metastasis by outcompeting Grb2 for the FGFR2 binding site. For example, it
has

been

previously

shown

that

over-expression

of

Plcγ1

induces

transformation of NIH3T3 fibroblasts (68,69).
Plcγ1 expression is also significantly high in colorectal cancer and colon
carcinoma cell lines compared with normal tissue (70). Additionally, several
breast carcinoma tissues have an elevated level of expression of nonphosphorylated Plcγ1 (71). For instance, certain breast cancer cell lines like
MDA-468 have high levels of membrane-associated non-phosphorylated Plcγ1
before stimulation; i.e. 69% of Plcγ1 is membrane bound under basal nonstimulated conditions compared to 4% in MCF-7 cells (72). Those cells also
express high levels of FGFR2 (73) and upon epidermal growth factor (EGF)
stimulation there is an insignificant increase in Plcγ1 membrane localization.
Therefore, in MDA-468 metastatic breast cancer cell line it is considered
possible that there is an up-regulation in the activity of the lipase upon receptor
mediated recruitment to the membrane.
A similar effect on oncogenesis and metastatic outcome can be observed in the
context of reduced cellular Grb2 concentration. By examining the data from
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ovarian cancer patient samples, there was a clear relationship between reduced
levels of Grb2 expression and metastasis. In those samples there was a
concomitant increase in the expression level of both Plcγ1 and FGFR2.
Thus, Grb2-mediated control of FGFR2 activity is imperative in maintaining
cellular homeostasis under basal non-stimulated conditions. Nevertheless,
FGFR2-Grb2 heterotetrameric complex formation through CSH3 interaction,
which has a weak affinity to the receptor, can leave the complex open to
competing SH3 domain binding which might result in an oncogenic outcome.

	
  

161	
  

PTEN-mediated activation of Akt is dictated by Grb2 expression levels
Plcγ1 has been previously shown to be up regulated upon Grb2 depletion in a
background of FGFR2 expression (59). Here the competition between Grb2 and
Plcγ1 for binding to FGFR2 in a concentration dependent manner appears to
cause a perturbation of membrane lipid concentration balance. This effect tends
to modulate PTEN activity and consequently Akt membrane localization,
phosphorylation and activation.
Thus, the novel results presented in Chapter 4 emphasize the importance of
Grb2-Plcγ1 competition in controlling the level of PIP2 critical for PTEN’s
association with the membrane. Previous studies have revealed that a
truncated version of this tumor suppressor gene missing the PIP2 binding motif
failed to associate with the membrane (74). PIP2 has also been shown to be
required for the induction of a conformational change in the structure of PTEN
by binding to the N-terminal domain of the latter. Even mutations in the Nterminus of PTEN have been shown to severely reduce the activity of PTEN by
possibly blocking the protein from binding PIP2 (75). Thus PTEN is suggested to
remain cytosolic in an inactive conformation where the catalytic domain is
masked by PIP2-binding domain. When PTEN binds on PIP2 on the membrane
a conformational change is induced that activates the phosphatase activity of
PTEN (76,77).
These studies provide strong in vitro and cell biological proof yet are lacking to
a certain level in the conditions and functional effects of PTEN/PIP2 interaction.
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Chapter 4 presents substantial evidence supporting the importance of PIP2 in
regulating PTEN activity in vivo and in vitro. It also shows how fluctuations in
the concentration of two non-phosphorylated proteins interacting with a receptor
via their SH3 domains can have drastic effect not only on migration, invasion,
and possibly metastasis but also on tumor development by controlling cellular
proliferation through PTEN, which in turn modulates Akt activity (Fig 5.1). One
can thus argue in favor of the importance of this mechanism where cellular PIP2
concentration regulates PTEN activity and a decrease in the level of this lipid
leads to loss of PTEN function mimicking the effects of tumor-derived mutations
identified in PIP2 binding motif—such as K13E, found in glioblastoma and
endometrial carcinoma, and S10N, found in lymphoma (78,79).
Akt (the read out for PTEN activity) has a higher level of membrane localization,
and phosphorylation under conditions where Plcγ1 outcompetes Grb2 for
FGFR2 binding or upon PTEN inhibition like in G2i cells or SF1670 treated cells
respectively. Also, it is important to note that under in vivo or in vitro conditions
(cell lysate based assays and in vitro reconstitution assays) where Plcγ1
replaces Grb2 on FGFR2 via its SH3 domain, PTEN is inactive. This is shown
to be a direct effect of the depletion of PIP2 required for the activity and
membrane localization of the phosphatase. Hence the end point of fluctuation of
Plcγ1/Grb2 concentration in cells and possibly tumors like UCEC is the
modulation of Akt activity via PTEN where Akt shows a negative correlation with
Grb2 and a simultaneous positive correlation with Plcγ1.
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As for the effect of such a mechanism on cellular function, the experiments are
based on the concept that in the multistep metastatic process, cancer cells at a
certain stage need to grow in an anchorage-independent manner and thus
survive without interacting with the cell’s substratum. Akt regulates such a
process where the inhibition of the Akt pathway leads to the formation of fewer
colonies in soft agar (21).
Colony formation is enhanced upon knocking down Grb2 but not Plcγ1 in a
background of FGFR2 expression compared to Ci/Pγi cells with FGFR2 and
endogenous levels of Grb2 and parental cells that express negligible levels of
FGFR2. Also, inhibiting PTEN increases the number of colonies formed, which
is an opposite effect to that observed with PI3K or Plcγ1 inhibition.
The soft agar assay results were validated in a xenograft mouse model, where
tumor formation seems to be enhanced in G2i cells compared to parental cells
,with negligible levels of FGFR2, and Ci cells. G2i tumor cells express higher
level of phosphorylated Akt (western blot and IHC results) compared to Ci cells.
Thus, the competition between Grb2 and Plcγ1 can be a critical factor in Akt
mediated tumor formation by controlling the levels of PTEN activation.
All of this, along with the effect seen upon inhibiting Akt, leads to the conclusion
that cellular proliferation is a direct result of Akt protein activation. These
observations are of great significance since they reveal the importance of Grb2
as a global regulator protein affecting several pathways. Also, they show that in
cancer development protein-protein competition could be as important as
genetic aberration and fluctuations in protein expression levels.
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Thus, SH3 domains, which have received little attention especially under nonstimulated conditions, have proven to be essential for normal cell function
where any shift in their concentration can tip the balance towards uncontrolled
cell proliferation and invasion.

a
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Fig 5.1 Grb2-Plcγ1 competition for binding to the C-terminus of FGFR2
regulates cell proliferation, migration and invasion.a) (1)Dimeric Grb2 binds
to two molecules of FGFR2 forming a heterotetramer. (2) Grb2 binding to
FGFR2 blocks the access of Plcγ1 to the receptor. (3) Steady state levels of
PI3K and PTEN activity and lack of activity of Plcγ1 maintains a normally low
level of PIP3. (4) Akt, which binds on PIP3 to get phosphorylated and
subsequently activated, cannot localize on the membrane efficiently. b) (1)
When the cellular level of Plcγ1 increases compared to Grb2, it replaces the
latter on FGFR2. (2) Receptor binding leads to the constitutive activation of
Plcγ1 lipase activity thus hydrolyzing PIP2 to IP3 and DAG depleting the
membrane of PIP2. (3) PIP2 is required for the stabilization and membrane
localization of PTEN thus PTEN activity is severely dampened while PI3K has a
steady state activity. Lack of activity of PTEN, which dephosphorylates PIP3
back to PIP2, causes a buildup of PIP3. (4) Accumulation of PIP3 induces a
surge in the activity of Akt following its membrane localization. (5) Increase in
Plcγ1 and Akt activity amplifies cellular proliferation, migration and invasive
potential.
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Chapter Six: Conclusion, Significance and Future
Directions
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Grb2 and Plcγ1 SH3 domain mediated competition for the same binding
site on FGFR2 regulates cell migration and invasion
Grb2-mediated control of FGFR2 activity is critical in maintaining cellular
homeostasis under basal non-stimulated conditions. This is achieved by the
formation of a heterotetrameric complex through Grb2CSH3 interactions (2).
Nonetheless the modest affinity of this complex leaves it vulnerable to
competing SH3 domain binding. Thus, under appropriate cellular conditions
Plcγ1 replaces Grb2 on FGFR2. The lipase in this case becomes constitutively
active leading to the depletion of PIP2 and a surge in intracellular calcium level
(59).
This concept is of great significance since it proposes a mechanism for a
phosphorylation-independent control of cell membrane constituency and
calcium flux leading to the phenotypic response of increased cell motility, which
has the potential to lead to metastasis in cancer cells.
In order to establish the solid connection between the intracellular balance
between Grb2 and Plcγ1 and metastasis, Ci, G2i and Pγi cells (containing a
luciferase vector to monitor metastasis via imaging and MRI) need to be
injected in an animal model (like nude mice). In this case, it is possible that G2i
cells will show a higher level of metastatic potential compared to Ci cells. If
Plcγ1 is indeed responsible for the metastatic outcome then knocking it down
will inhibit the metastatic process.
Thus, dependence of this phenotype on the relative intracellular concentrations
of Grb2 and Plcγ1 in a FGFR2 background suggests that the expression levels
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of these proteins could provide reliable markers for metastatic outcome in
patients. This is critical when studying and testing drugs that aim at targeting
Grb2 (80-87) since the factor of Grb2/Plcγ1/FGFR2 concentration should be
taken into consideration or else the metastatic potential of the primary tumor will
be enhanced by shifting the balance towards Plcγ1 and allowing for its
constitutive binding to FGFR2 and the consequent uncontrollable up-regulation
of its activity.
Also, since Grb2 in this case is acting as a controlling factor that to some extent
reduces cell migration and invasion, then manipulating its level of expression
can potentially be of great significance in inhibiting metastasis. This rationale
can be employed in performing a database search to further investigate the
Grb2 specific micro RNAs (miRNA) and their role in silencing Grb2 gene
expression.
Prospective candidates and specifically in ovarian cancer can be considered
oncogenic and targeting them in cell lines to begin with can open the door for
the investigation of a novel therapeutic cancer type dependent anti-metastatic
agent.
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PTEN-mediated activation of Akt is dictated by Grb2 expression levels
It appears that through the resultant perturbation of the phospholipid
constitution of the plasma membrane, depletion of Grb2 has an oncogenic
outcome. In this work we investigate the combined effects of enzyme-regulated
concentrations of PIP2 and PIP3 on Akt signal transduction and demonstrate
that these can be directly linked to cellular Grb2 concentration.
Thus, this work provides a novel entrée in understanding the conditions
triggering an anomalous Akt response. This provides groundwork for future
studies in animal models to show that fluctuating the concentration of Grb2 SH3
domain instead of full length protein (as shown in this work) can control for
Plcγ1-FGFR2 association and the subsequent effect on PIP2 level. This can be
the basis of therapeutic agents that mitigate the aberrant Akt oncogenic
signaling pathway that drives many cancers, and can become an alternative or
adjunctive (secondary) approach to the use of numerous kinase inhibitors,
many of which are toxic, and can be highly non-specific when used to dampen
the aberrant hyperactivation of Akt. It can also be exploited as a diagnostic tool
especially that it is becoming more crucial to develop methods to identify those
patients with tumors driven by Akt-based molecular abnormalities (88,89) or
when other means of Akt pathway inhibition can be used to enhance the effect
of radiation or traditional chemotherapeutic drugs (90-95).
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Taken together, the current findings offer a novel concept namely:“The role of
SH3 domains competition in tumor development and metastasis” that has the
potential to become the foundation of several intervention strategies in PTENmediated disease treatment modalities like the pharmacotherapy of cancer.
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